CA2257104C - Methylation specific detection - Google Patents

Methylation specific detection Download PDF

Info

Publication number
CA2257104C
CA2257104C CA002257104A CA2257104A CA2257104C CA 2257104 C CA2257104 C CA 2257104C CA 002257104 A CA002257104 A CA 002257104A CA 2257104 A CA2257104 A CA 2257104A CA 2257104 C CA2257104 C CA 2257104C
Authority
CA
Canada
Prior art keywords
seq
nos
nucleic acid
primer pair
target sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002257104A
Other languages
French (fr)
Other versions
CA2257104A1 (en
Inventor
James G. Herman
Stephen B. Baylin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/656,716 external-priority patent/US5786146A/en
Application filed by School of Medicine of Johns Hopkins University filed Critical School of Medicine of Johns Hopkins University
Priority to CA2612690A priority Critical patent/CA2612690C/en
Publication of CA2257104A1 publication Critical patent/CA2257104A1/en
Application granted granted Critical
Publication of CA2257104C publication Critical patent/CA2257104C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Abstract

The present invention provides a method of PCR, methylation specific PCR
(MSP), for rapid identification of DNA methylation patterns in a CpG-containing nucleic acid. MSP uses the PCR reaction itself to distinguish between methylated and unmethylated DNA, which adds an improved sensitivity of methylation detection.

Description

METHYLATION SPECIFIC DETECTION
Field of the Invention The present invention relates generally to regulation of gene expression, and more specifically to a method of determining the DNA methylation status of CpG
sites in a given locus.

Backaround of the Invention In higher order eukaryotes DNA is methylated only at cytosines located 5' to guanosine in the CpG
dinucleotide. This modification has important regulatory effects on gene expression, especially when involving CpG
rich areas, known as CpG islands, located in the promoter regions of many genes. While almost all gene-associated islands are protected from methylation on autosomal chromosomes, extensive methylation of CpG islands has been associated with transcriptional inactivation of selected imprinted genes and genes on the inactive X -chromosome of females. Abberant methylation of normally unmethylated CpG islands has been described as a frequent event in immortalized and transformed cells, and has been associated with transcriptional inactivation of defined tumor suppressor genes in human cancers.
Human cancer cells typically contain somatically altered genomes, characterized by mutation, amplification, or deletion of critical genes. In addition, the DNA template from human cancer cells often displays somatic changes in DNA methylation (E.R. Fearon, et al., Cell, 61:759, 1990; P.A. Jones, et al., Cancer Res., 46:461, 1'986; R. Holliday, Science, 238 : 163, 1987;
A. De Bustros, et al., Proc. Na tI . Acad. Sci., USA, 85:5693, 1988); P.A. Jones, et al., Adv. Cancer Res., 54:1, 1990; S.B. Baylin, et al., Cancer Cells, 3:383, 1991; M. Makos, et al., Proc. Natl. Acad. Sci., USA, $9: 1929, 1992; N. Ohtani-Fujita, et al., Oncogene, 8:1063, 1993). However, the precise role of abnormal DNA
methylation in human tumorigenesis has not been estab-lished. DNA methylases transfer methyl groups from the universal methyl donor S-adenosyl methionine to specific sites on the DNA. Several biological functions have been attributed to the methylated bases in DNA. The most established biological function is the protection of the DNA from digestion by cognate restriction enzymes. The restriction modification phenomenon has, so far, been observed only in bacteria. Mammalian cells, however, possess a different methylase that exclusively methylates cytosine residues on the DNA, that are 5' neighbors of guanine (CpG). This methylation has been shown by several lines of evidence to play a role in gene activity, cell differentiation, tumorigenesis, X-chromosome inactivation, genomic imprinting and other major biological processes (Razin, A., H., and Riggs, R.D. eds. in DNA Methylation Biochemistry and Biological Significance, Springer-Verlag, New York, 1984).
A CpG rich region, or "CpG island", has recently been identified at 17p13.3, which is aberrantly hypermethylated in multiple common types of human cancers (Makos, M., et al., Proc. Nat1. Acad. Sci. USA, 89:1929, 1992; Makos, M., et al., Cancer Res., 53:2715, 1993;
Makos, M., et al., Cancer Res. 83:2719, 1993). This h-ypermethylation coincides with timing and frequency of 17p losses and p53 mutations in brain, colon, and renal cancers. Silericed gene transcription associated with hypermethylation of the normally unmethylated promoter region CpG islands has been implicated as an alternative mechanism to mutations of coding regions for inactivation of tumor suppressor genes (Baylin, S.B., et al., Cancer Cells, 3:383, 1991; Jones, P.A. and Buckley, J.D., Adv.
Cancer Res., 54:1-23, 1990). This change has now been associated with the loss of expression of VHL, a renal cancer tumor suppressor gene on 3p (J.G. Herman, et al., Proc. Nat1. Acad. Sci. USA, 91:9700-9704, 1994), the estrogen receptor gene on 6q (Ottaviano, Y.L., et al., Cancer Res., 54:2552, 1994) and the H19 gene on 11p (Steenman, M.J.C., et al., Nature Genetics, 7:433, 1994).
In eukaryotic cells, methylation of cytosine residues that are immediately 5' to a guanosine, occurs predominantly in CG poor regions (Bird, A., Nature, 321:209, 1986). In contrast, discrete regions of CG
dinucleotides called CpG islands remain unmethylated in normal cells, except during X-chromosome inactivation (Migeon, et al., supra) and parental specific imprinting (Li, et al., Nature, 366:362, 1993) where methylation of 5' regulatory regions can lead to transcriptional repression. De novo methylation of the Rb gene has been demonstrated in a small fraction of retinoblastomas (Sakai, et al., Am. J. Hum. Genet., 48:880, 1991), and recently, a more detailed analysis of the VHL gene showed aberrant methylation in a subset of sporadic renal cell carcinomas (Herman, et al., Proc. Natl. Acad. Sci., U.S.A., 91:9700, 1994). Expression of a tumor suppressor gene can also be abolished by de novo DNA methylation of a normally unmethylated 5' CpG island (Issa, et al., Nature Genet., 7:536, 1994; Herman, et al., supra; Merlo, et al., Nature Med., 1:686, 1995; Herman, et al., Cancer Res., 56:722, 1996; Graff, et al., Cancer Res., 55:5195, 1995; Herman, et al., Cancer Res., 55:4525, 1995).

Most of the methods developed to date for detection of methylated cytosine depend upon cleavage of the phosphodiester bond alongside cytosine residues, using either methylation-sensitive restriction enzymes or reactive chemicals such as hydrazine which differentiate between cytosine and its 5-methyl derivative. The use of methylation-sensitive enzymes suffers from the disadvantage that it is not of general applicability, since only a limited proportion of potentially methylated sites in the genome can be analyzed. Genomic sequencing protocols which identify a 5-MeC residue in genomic DNA
as a site that is not cleaved by any of the Maxam Gilbert -sequencing reactions, are a substantial improvement on the original genomic sequencing method, but still suffer disadvantages such as the requirement for large amount of genomic DNA and the difficulty in detecting a gap in a sequencing ladder which may contain bands of varying intensity.
Mapping of methylated regions in DNA has relied primarily on Southern hybridization approaches, based on the inability of methylation-sensitive restriction enzymes to cleave sequences which contain one or more methylated CpG sites. This method provides an assessment of the overall methylation status of CpG
islands, including some quantitative analysis, but is relatively insensitive, requires large amounts of high molecular weight DNA and can only provide information about those CpG sites found within sequences recognized by methylation-sensitive restriction enzymes. A more sensitive method of detecting methylation patterns combines the use of methylation-sensitive enzymes and the polymerase chain reaction (PCR). After digestion of DNA
with the enzyme, PCR will amplify from primers flanking the restriction site only if DNA cleavage was prevented by methylation. Like Southern-based approaches, this method can only monitor CpG methylation in methylation-sensitive restriction sites. Moreover, the restriction of unmethylated DNA must be complete, since any uncleaved DNA will be amplified by PCR yielding a false positive result for methylation. This approach has been useful in studying samples where a high percentage of alleles of interest are methylated, such as the study of imprinted genes and X-chromosome inactivated genes. However, difficulties in distinguishing between incomplete restriction and low numbers of methylated alleles make this approach unreliable for detection of tumor suppressor gene hypermethylation in small samples where methylated alleles represent a small fraction of the population.
Another method that avoids the use of restriction endonucleases utilizes bisulfite treatment of DNA to convert all unmethylated cytosines to uracil. The altered DNA is amplified and sequenced to show the methylation status of all CpG sites. However, this method is technically difficult, labor intensive and without cloning amplified products, it is less sensitive than Southern analysis, requiring approximately 10% of the alleles to be methylated for detection.
Identification of the earliest genetic changes in tumorigenesis is a major focus in molecular cancer research. Diagnostic approaches based on identification of these changes are likely to allow implementation of early detection strategies and novel therapeutic approaches targeting these early changes might lead to more effective cancer treatment.

Summary of the Invention The precise mapping of DNA methylation patterns in CpG islands has become essential for understanding diverse biological processes such as the regulation of imprinted genes, X-chromosome inactivation, and tumor suppressor gene silencing in human cancer. The present invention provides a method for rapid assessment of the methylation status of any group of CpG sites within a CpG
island, independent of the use of methylation-sensitive restriction enzymes. Despite the knowledge of those of skill in the art regarding the use of PCR and the use of bisulfite modification, independently, until the present invention, no one had prepared primers that were specific for the bisulfite reaction such that the PCR reaction itself was used to distinguish between the chemically modified methylated and unmethylated DNA.
The method of the invention includes modification of DNA by sodium bisulfite or a comparable agent which converts all unmethylated but not methylated cytosines to uracil, and subsequent amplification with primers specific for methylated versus unmethylated DNA. This method of "methylation specific PCR" or MSP, requires only small amounts of DNA, is sensitive to 0.1 % of methylated alleles of a given CpG island locus, and can be performed on DNA extracted from paraffin-embedded samples, for example. MSP eliminates the false positive results inherent to previous PCR-based approaches which relied on differential restriction enzyme cleavage to distinguish methylated from unmethylated DNA.
In a particular aspect of the invention, MSP is useful for identifying promoter region hypermethylation changes associated with transcriptional inactivation in tumor suppressor genes, for example, p16, p15, E-cadherin and VHL, in human neoplasia. Other genes that are shown to be methylated include the estrogen receptor,MDGI, GST-pi, calcitonin, HIC-1, endothelin B receptor, TIMP-2, 06-MGMT, MLH1, MSH2, and GFAP. Of those, the estrogen receptor, MDGI, GST-pi, calcitonin, HIC-1, endothelin B
receptor, TIMP-2, 06-MGMT, and MLH1 were shown by MSP to be hypermethylated in neoplastic tissue as compared with normal tissue. For the first time, the invention provides evidence that TIMP-2, a tissue inhibitor of metalloproteinases, is hypermethylated in neoplastic tissue as compared with normal tissue.

Brief Description of the Drawincrs Figure 1 shows genomic sequencing of p16. The sequence shown has the most 5' region at the bottom of the gel, beginning at +175 in relation to a major transcriptional start site (Hara, et al., Mol. Cell Biol., 16:859, 1996). All cytosines in the unmethylated cell line H249 have been converted to thymidine, while all C's in CpG dinucleotides in the methylated cell H157 remains as C, indicating methylation. ] enclosed a BstUI
site which is at -59 in relation to the transnational start site in Genbank sequence U12818 (Hussussian, et al., Nat. Genet., 8:15, 1994), but which is incorrectly identified as CGCA in sequence X94154 (Hara, et al., supra). This CGCG site represents the 3' location of the sense primer used for p16 MSP.
Figure 2; panels A-E, show polyacrylamide gels with the Methylation Specific PCR products of p16. Primer sets used for amplification are designated as unmethylated (U), methylated (M), or unmodified/wild-type 5(W).* designates the molecular weight marker pBR322-Mspl digest. Panel A shows amplification of bisulfite-treated DNA from cancer cell lines and normal lymphocytes, and untreated DNA (from cell line H249). Panel B shows mixing of various amount of H157 DNA with 1 pg of H249 DNA prior to bisulfite treatment to assess the detection sensitivity of MSP for methylated alleles. Modified DNA
from a primary lung cancer sample and normal lung are also shown. Panel C shows amplification with the p16-U2 (U) primers, and p16-M2 (M) described in Table 1. Panel D
shows the amplified p16 products of panel C restricted with BstUI(+) or not restricted (-).
Panel E shows results of testing for regional methylation of CpG islands with MSP, -using sense primers p16-U2 (U) and p16-M2 (M), which are methylation specific, and an antisense primer which is not methylation specific.
Figure 3, panels A-E, show polyacrylamide gels of MSP products from analysis of several genes. Primer sets used for amplification are not designated as unmethylated (U), methylated (M), or unmodified/wild-type (W). *
designates the molecular weight marker pBR322-Mspl digest and ** designates the 123bp molecular weight marker. All DNA samples were bisulfite treated except those designated untreated. Panel A shows the results from MSP
for p15. Panel B shows the p15 products restricted with BstUI (+) or not restricted (-). Panel C shows the products of MSP for VHL. Panel D shows the VHL products restricted with BstUI(+) or not restricted (-). Panel E
shows the products of MSP for E-cadherin.
Description of the Preferred Embodiments The present invention provides methylation specific PCR (MSP) for identification of DNA methylation patterns. MSP uses the PCR reaction itself to distinguish between modified methylated and unmethylated DNA, which adds an improved sensitivity of methylation detection.
Unlike previous genomic sequencing methods for methylation identification which utilizes amplification primers which are specifically designed to avoid the CpG
sequences, MSP primers themselves are specifically designed to recognize CpG sites to take advantage of the differences in methylation to amplify specific products to be identified by the invention assay.
As illustrated in the Examples below, MSP provides significant advantages over previous PCR and other methods used for assaying methylation. MSP is markedly more sensitive than Southern analyses, facilitating detection of low numbers of methylated alleles and the study of DNA from small samples. MSP allows the study of paraffin-embedded materials, which could not previously be analyzed by Southern analysis. MSP also allows examination of all CpG sites, not just those within sequences recognized by methylation-sensitive restriction enzymes. This markedly increases the number of such sites which can be assessed and will allow rapid, fine mapping of methylation patterns throughout CpG rich regions. MSP
also eliminates the frequent false positive results due to partial digestion of methylation-sensitive enzymes inherent in previous PCR methods for detecting methylation. Furthermore, with MSP, simultaneous detection of unmethylated and methylated products in a single sample confirms the integrity of DNA as a template for PCR and allows a semi-quantitative assessment of allele types which correlates with results of Southern analysis. Finally, the ability to validate the amplified product by differential restriction patterns is an additional advantage.
The only technique that can provide more direct analysis than MSP for most CpG sites within a defined region is genomic sequencing. However, MSP can provide similar information and has the following advantages.
First, MSP is much simpler and requires less than genomic sequencing, with a typical PCR and gel analysis taking 4-6 hours. In contrast, genomic sequencing, amplification, cloning, and subsequent sequencing may take days. MSP
also avoids the use of expensive sequencing reagents and the use of radioactivity. Both of these factors make MSP
better suited for the analysis of large numbers of samples. Third, the use of PCR as the step to distinguish methylated from unmethylated DNA in MSP allows for significant increase in the sensitivity of methylation detection. For example, if cloning is not used prior to genomic sequencing of the DNA, less than 10% methylated DNA in a background of unmethylated DNA cannot be seen (Myohanen, et al., supra). The use of PCR and cloning does allow sensitive detection of methylation patterns in very small amounts of DNA by genomic sequencing (Frommer, et al., Proc. Natl. Acad. Sci. USA, 89:1827, 1992; Clark, et al., Nucleic Acids Research, 22:2990, 1994). However, this means in practice that it would require sequencing analysis of 10 clones to detect 10% methylation, 100 clones to detect 1% methylation, and to reach the level of sensitivity we have demonstrated with MSP (1:1000), one would have to sequence 1000 individual clones.
In a first embodiment, the invention provides a method for detecting a methylated CpG-containing nucleic acid, the method including contacting a nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, amplifying the CpG-containing nucleic acid in the specimen by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers distinguish between modified methylated and non-methylated nucleic acid and detecting the methylated nucleic acid. It is understood that while the amplification step is optional, it is desirable in the preferred method of the invention. The method of the invention relies on the PCR reaction itself to distinguish between modified (e.g., chemically modified) methylated and unmethylated DNA.
The term "modifies" as used herein means the conversion of an unmethylated cytosine to another nucleotide which will distinguish the unmethylated from the methylated cytosine. Preferably, the agent modifies unmethylated cytosine to uracil. Preferably, the agent used for modifying unmethylated cytosine is sodium bisulfite, however, other agents that similarly modify unmethylated cytosine, but not methylated cytosine can also be used in the method of the invention. Sodium bisulfite (NaHSO3) reacts readily with the 5,6-double bond of cytosine, but poorly with methylated cytosine.
Cytosine reacts with the bisulfite ion to form a sulfonated cytosine reaction intermediate which is susceptible to deamination, giving rise to a sulfonated uracil. The sulfonate group can be removed under alkaline conditions, resulting in the formation of uracil..Uracil is recognized as a thymine by Taq polymerase and therefore upon PCR, the resultant product contains cytosine only at the position where 5-methylcytosine occurs in the starting template DNA.
The primers used in the invention for amplification of the CpG-containing nucleic acid in the specimen, after bisulfite modification, specifically distinguish between untreated or unmodified DNA, methylated, and non-methylated DNA. MSP primers for the non-methylated DNA preferably have a T in the 3' CG pair to distinguish it from the C retained in methylated DNA, and the compliment is designed for the antisense primer.
MSP primers usually contain relatively few Cs or Gs in the sequence since the Cs will be absent in the sense primer and the Gs absent in the antisense primer (C
becomes modified to U (uracil) which is amplified as T
(thymidine) in the amplification product).
The primers of the invention embrace o-ligonucleotides of sufficient length and appropriate sequence so as to provide specific initiation of polymerization on a significant number of nucleic acids in the polymorphic locus. Specifically, the term "primer" as used herein refers to a sequence comprising two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and most preferably more than 8, which sequence is capable of initiating synthesis of a primer extension product, which is substantially complementary to a polymorphic locus strand.
Environmental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If_double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxy ribonucleotide. The primer must be suffi-ciently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization.
The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The oligonucleotide primer typically contains 12-20 or more nucleotides, although it may contain fewer nucleotides.
Primers of the invention are designed to be "substantially" complementary to each strand of the genomic locus to be amplified and include the appropriate G or C nucleotides as discussed above. This means that the primers must be sufficiently complementary to hybridize with their respective strands under conditions which allow the agent for polymerization to perform. In other words, the primers should have sufficient complementarity with the 5' and 3' flanking sequences to hybridize therewith and permit amplification of the genomic locus. While exemplary primers are provided in SEQ ID NO:105-208, it is understood that any primer that hybridizes with the target sequences in SEQ ID NO: 1-104 is included in the invention and is useful in the method of the invention for detecting methylated nucleic acid, as described.
Oligonucleotide primers of the invention are employed in the amplification process which is an enzymatic chain reaction that produces exponential quantities of target locus relative to the number of reaction steps involved. Typically, one primer is complementary to the negative (-) strand of the locus and the other is complementary to the positive (+) strand.
Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA Polymerase I(Klenow) and nucleotides, results in newly synthesized + and - strands containing the target locus sequence. Because these newly synthesized sequences are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target locus sequence) defined by the primer. The product of the chain reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed.
The oligonucleotide primers of the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1859-1862, 1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No.
4,458,066.
Any nucleic acid specimen, in purified or nonpurified form, can be utilized as the starting nucleic acid or acids, provided it contains, or is suspected of containing, the specific nucleic acid sequence containing the target locus (e.g., CpG). Thus, the process may employ, for example, DNA or RNA, including messenger RNA, wherein DNA or RNA may be single stranded or double stranded. In the event that RNA is to be used as a template, enzymes, and/or conditions optimal for reverse transcribing the template to DNA would be utilized. In addition, a DNA-RNA hybrid which contains one strand of each may be utilized. A mixture of nucleic acids may also be employed, or the nucleic acids produced in a previous amplification reaction herein, using the same or different primers may be so utilized. The specific nucleic acid sequence to be amplified, i.e., the target locus, may be a fraction of a larger molecule or can be present initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid.
It is not necessary that the sequence to be amplified be present initially in a pure form; it may be a minor fraction of a complex mixture, such as contained in whole human DNA.
The nucleic acid-containing specimen used for detection of methylated CpG may be from any source including brain, colon, urogenital, hematopoietic, thymus, testis, ovarian, uterine, prostate, breast, colon, lung and renal tissue and may be extracted by a variety of techniques such as that described by Maniatis, et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY, pp 280, 281, 1982).
If the extracted sample is impure (e.g., plasma, serum, stool, ejaculate, sputum, saliva, cerebrospinal fluid or blood or a sample embedded in parrafin), it may be treated before amplification with an amount of a reagent effective to open the cells, fluids, tissues, or animal cell membranes of the sample, and to expose and/or separate the strand(s) of the nucleic acid(s). This lysing and nucleic acid denaturing step to expose and separate the strands will allow amplification to occur much more readily.
Where the target nucleic acid sequence of the sample contains two strands, it is necessary to separate the strands of the nucleic acid before it can be used as the template. Strand separation can be effected either WO 97/46705 II'CT/US97/09533 as a separate step or simultaneously with the synthesis of the primer extension products. This strand separation can be accomplished using various suitable denaturing conditions, including physical, chemical, or enzymatic means, the word "denaturing" includes all such means.
One physical method of separating nucleic acid strands involves heating the nucleic acid until it is denatured.
Typical heat denaturation may involve temperatures ranging from about 800 to 105 C for times ranging from about 1 to 10 minutes. Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or by the enzyme RecA, which has helicase activity, and in the presence of riboATP, is known to denature DNA. The reaction conditions suitable for strand separation of nucleic acids with helicases are described by Kuhn Hoffmann-Berling (CSH-Quantitative Biology, 43:63, 1978) and techniques for using RecA are reviewed in C. Radding (Ann. Rev. Genetics, I6:405-437, 1982).
When complementary strands of nucleic acid or acids are separated, regardless of whether the nucleic acid was originally double or single stranded, the separated strands are ready to be used as a template for the synthesis of additional nucleic acid strands. This synthesis is performed under conditions allowing hybridization of primers to templates to occur.
Generally synthesis occurs in a buffered aqueous solution, preferably at a pH of 7-9, most preferably about 8. Preferably, a molar excess (for genomic nucleic acid, usually about 10e:1 primer:template) of the two oligonucleotide primers is added to the buffer containing the separated template strands. It is understood, however, that the amount of complementary strand may not be known if the process of the invention is used for diagnostic applications, so that the amount of primer relative to the amount of complementary strand cannot be determined with certainty. As a practical matter, however, the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a mixture of complicated long-chain nucleic acid strands. A large molar excess is preferred to improve the efficiency of the process.
The deoxyribonucleoside triphosphates dATP, dCTP, dGTP, and dTTP are added to the synthesis mixture, either separately or together with the primers, in adequate amounts and the resulting solution is heated to about 90 -100 C from about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool to room temperature, which is preferable for the primer hybridization. To the cooled mixture is added an appropriate agent for effecting the primer extension reaction (called herein "agent for polymerization"), and the reaction is allowed to occur under conditions known in the art. The agent for polymerization may also be added together with the other reagents if it is heat stable. This synthesis (or amplification) reaction may occur at room temperature up to a temperature above which the agent for polymerization no longer functions. Thus, for example, if DNA
polymerase is used as the agent, the temperature is generally no greater than about 40 C. Most conveniently the reaction occurs at room temperature.
The agent for polymerization may be any compound or system which will function to accomplish the synthesis of primer extension products, including enzymes.
Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Klenow fragment of E. coli DNA
polymerase I, T4 DNA polymerase, other available DNA
polymerases, polymerase muteins, reverse transcriptase, -and other enzymes, including heat-stable enzymes (i.e., those enzymes which perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation). Suitable enzymes will facilitate combination of the nucleotides in the proper manner to form the primer extension products which are complementary to each locus nucleic acid strand.
Generally, the synthesis will be initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths. There may be agents for polymerization, however, which initiate synthesis at the 5' end and proceed in the other direction, using the same process as described above.
In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.
An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1%
SDS at about room temperature (low stringency WO 97/46705 1'CT/US97/09533 conditions); 0.2 x SSC/0.1% SDS at about 42 C (moderate stringency conditions); and 0.1 x SSC at about 68 C (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.
Preferably, the method of amplifying is by PCR, as described herein and as is commonly used by those of ordinary skill in the art. Alternative methods of amplification have been described and can also be employed as long as the methylated and non-methylated loci amplified by PCR using the primers of the invention is similarly amplified by the alternative means.
The amplified products are preferably identified as methylated or non-methylated by sequencing. Sequences amplified by the methods of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, et al., Bio/Technology, 3:1008-1012, 1985), allele-specific oligonucleotide (ASO) probe analysis (Conner, et al., Proc. Nat1. Acad. Sci. USA, 80:278, 1983), oligonucleotide ligation assays (OLAs) (Landegren, et al., Science, 241:1077, 1988), and the like.
Molecular techniques for DNA analysis have been reviewed (Landegren, et al., Science, 242:229-237, 1988).
Optionally, the methylation pattern of the nucleic acid can be confirmed by restriction enzyme digestion and Southern blot analysis. Examples of methylation sensitive restriction endonucleases which can be used to detect 5'CpG methylation include SmaI, SacII, EagI, MspI, HpaII, BstUI and BssHII, for example.
The invention provides a method for detecting a cell having a methylated CpG island or a cell proliferative disorder associated with methylated CpG in a tissue or biological fluid of a subject, comprising contacting a target cellular component suspected of expressing a gene having a methylated CpG or having a CpG-associated disorder, with an agent which binds to the component. The target cell component can be nucleic acid, such as DNA or RNA, or protein. When the component is nucleic acid, the reagent is a nucleic acid probe or PCR primer. When the cell component is protein, the reagent is an antibody probe. The probes can be detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator, or an enzyme. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.
Actively transcribed genes generally contain fewer methylated CGs than the average number in DNA.
Hypermethylation can be detected by restriction endonuclease treatment and Southern blot analysis.
Therefore, in a method of the invention, when the cellular component detected is DNA, restriction endonuclease analysis is preferable to detect hypermethylation of the promoter for example. Any restriction endonuclease that includes CG as part of its recognition site and that is inhibited when the C is methylated, cari be utilized. Preferably, the methylation sensitive restriction endonuclease is BssHII, MspI, or HpaII, used alone or in combination. Other methylation sensitive restriction endonucleases will be known to those of skill in the art.
For purposes of the invention, an antibody or nucleic acid probe specific for a gene or gene product may be used to detect the presence of methylation either by detecting the level of polypeptide (using antibody) or methylation of the polynucleotide (using nucleic acid probe) in biological fluids or tissues. For antibody based detection, the level of the polypeptide is compared with the level of polypeptide found in a corresponding "normal" tissue. Oligonucleotide primers based on any coding sequence region of the promoter in the TIMP-2, estrogen receptor, GST-pi, calcitonin, HIC-1 or MLH1 sequence, for example, are useful for amplifying DNA, for example by PCR. These genes are merely listed as examples and are not meant to be limiting. Any specimen containing a detectable amount of polynucleotide or antigen can be used. Preferably the subject is human.
The present invention provides the finding that TIMP-2 is methylated in cancer tissue as compared to normal tissue. For example, TIMP-2 was found to be methylated in colon cancer tissue but not in normal colon tissue. The method for detecting a cell expressing a gene such as TIMP-2, or a cell proliferative disorder associated with methylation of CpG containing TIMP-2, or any gene including those described above, can be utilized for detection of residual cancer or other malignancies in a subject in a state of clinical remission.
Additionally, the method for detecting polypeptide in cells is useful for detecting a cell proliferative disorder by measuring the level of polypeptide in cells expressing the polypeptide, in a suspect tissue in comparison with the polypeptide expressed in normal cells or tissue. Using the method of the invention, expression of any gene, such as TIMP-2, can be identified in a cell and the appropriate course of treatment can be employed (e.g., sense gene therapy or drug therapy). The expression pattern of the gene, e.g., TIMP-2, may vary with the stage of malignancy of a cell, therefore, a sample such as breast or colon tissue can be screened with a panel of gene or gene product specific reagents (i.e., nucleic acid probes or antibodies) to detect gene expression, e.g., TIMP-2, and diagnose the stage of malignancy of the cell.
Monoclonal antibodies can be used in the method of the invention, for example, in immunoassays in liquid phase or bound to a solid phase carrier. In addition, the monoclonal antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize monoclonal antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format.
Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the monoclonal antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.
The term "immunometric assay" or "sandwich immunoassay", includes simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.
Monoclonal antibodies can be bound to many different carriers and used to detect the presence of TIMP-2. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of-the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such using routine experimentation.
For purposes of the invention, TIMP-2 may be detected by the monoclonal antibodies when present in biological fluids and tissues. Any sample containing a detectable amount of TIMP-2 can be used. A sample can be a liquid such as ejaculate, urine, saliva, cerebrospinal fluid, blood, serum and the like, or a solid or semi-solid such as tissues, feces, and the like, or, alternatively, a solid tissue such as those commonly used in histological diagnosis.
In performing the assays it may be desirable to include certain "blockers" in the incubation medium (usually added with the labeled soluble antibody). The "blockers" are added to assure that non-specific proteins, proteases, or anti-heterophilic immunoglobulins to anti-TIMP-2"immunoglobulins present in the experimental sample do not cross-link or destroy the antibodies on the solid phase support, or the radiolabeled indicator antibody, to yield false positive or false negative results. The selection of "blockers"
therefore may add substantially to the specificity of the assays described in the present invention.
In using a monoclonal antibody for the in vivo detection of antigen, the detectably labeled monoclona 1 antibody is given in a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the TIMP-2 antigen for which the monoclonal antibodies are specific.
The concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having TIMP-2 is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.
As a rule, the dosage of detectably labeled monoclonal antibody for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. The dosage of monoclonal antibody can vary from about 0.001 mg/m2 to about 500 mg/mZ, preferably 0.1 mg/m2 to about 200 mg/m2, most preferably about 0.1 mg/m2 to about 10 mg/m2. Such dosages may vary, for example, depending on whether multiple injections are given, tumor burden, and other factors known to those of skill in the art.
For in vivo diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for in vivo diagnosis is that the half-life of the radioisotope be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host is minimized.
Ideally, a radioisotope used for in vivo imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may be readily detected by conventional gamma cameras.
A monoclonal antibody useful in the method of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR).
In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include 157Gd' 55Mn, 162Dy, 52Cr, and 56Fe.
Monoclonal antibodies used in the method of the invention can be used to monitor the course of amelioration of TIMP-2 associated cell proliferative disorder. Thus, by measuring the increase or decrease in the number of cells expressing TIMP-2 or changes in TIMP-2 present in various body fluids, it would be possible to determine whether a particular therapeutic regiment aimed at ameliorating the disorder is effective.
The teritm "modulate" envisions the suppression of methylation of TIMP-2 (e.g., promoter) or augmentation of TIMP-2 gene expression when TIMP-2 is under-expressed.
When a cell proliferative disorder is associated with TIMP-2 expression, such methylation suppressive reagents as 5-azacytadine can be introduced to a cell.
Alternatively, when a cell proliferative disorder is associated with under-expression of TIMP-2 polypeptide, a sense polynucleotide sequence (the DNA coding strand) encoding the promoter region or the promoter operably linked to the structural gene, or TIMP-2 polypeptide can be introduced into the cell.
The present invention also provides gene therapy for the treatment of cell proliferative disorders which are mediated by TIMP-2. Such therapy would achieve its therapeutic effect by introduction of the appropriate TIMP-2 polynucleotide which contains either a normal TIMP-2 promoter region alone or in combination with a TIMP-2 structural gene (sense), into cells of subjects having the proliferative disorder. Alternatively, the TIMP-2 structural gene could be introduced operably linked to a heterologous promoter. Delivery of sense TIMP-2 promoter polynucleotide constructs can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system.
The promoter polynucleotide sequences used in the method of the invention may be the native, unmethylated sequence or, alternatively, may be a sequence in which a nonmethylatable analog is substituted within the sequence. Preferably, the analog is a nonmethylatable analog of cytidine, such as 5-azacytadine. Other analogs will be known to those of skill in the art.
Alternatively, such nonmethylatable analogs could be administered to'a subject as drug therapy, alone or simultaneously with a sense promoter for TIMP-2 or a sense promoter operably linked with the structural gene for the corresponding gene (e.g., TIMP-2 promoter with TIMP-2 structural gene).
The invention also relates to a medicament or pharmaceutical composition comprising a TIMP-2 promoter polynucleotide or a TIMP-2 promoter polynucleotide operably linked to the TIMP-2 structural gene, respectively, in a pharmaceutically acceptable excipient or medium wherein the medicament is used for therapy of TIMP-2 associated cell proliferative disorders.
The invention also provides the use of MSP for in situ methylation analysis. For example, MSP can be used to detect methylation of DNA in the nucleus of an intact cell. A tissue section, a cell or population of cells is placed or immobilized on a solid support (e.g., a slide) and MSP primers used directly on the cell for amplification of the appropriate sequences. The primers are typically detectably labeled with a reporter means, e.g., fluorescent label. Alternatively, a probe that detects or hybridizes with the MSP amplified sequences is used to detect amplification of methylated sequences. In situ methylation analysis using MSP is useful, for example, in detecting nucleic acid having a mutant nucleotide sequence associated with a primary tumor in the adjacent histopathologic surgical margins and more distant tissues, such as regional lymph nodes, which are apparently "normal" when examined by standard histological techniques. Using MSP, it is possible to detect target nucleic acids from cells previously associated with a large number of disease states which are present in tissue that appears normal. MSP in situ can be used as 'an adjunct to cytopathology, to screen high-risk populations and to monitor high risk patients undergoing chemoprevention or chemotherapy.
Exemplary target polynucleotide sequences to which the primer of the invention hybridizes have a sequence as listed below.

SEO ID NO.
Wild type p16 5'-GCGGTCCGCCCCACCCTCTG-3'; 1 5'-CCACGGCCGCGGCCCG- 3'; 2 Methylated p16-1* 5'-GCGATCCGCCCCACCCTCTAATAA-3'; 3 5'-TTACGGTCGCGGTTCGGGGTC-3'; 4 Unmethylated p16-1 5'-ACAATCCACCCCACCCTCTAATAA-3'; 5 5'-TTATGGTTGTGGTTTGGGGTTG-3'; 6 Methylated p16-2 5'-GCGATCCGCCCCACCCTCTAATAA-3'; 7 51-CGGTCGGAGGTCGATTTAGGTGG-3'; 8 Unmethylated p16-2 5'-ACAATCCACCCCACCCTCTAATAA-3'; 9 5'-TGGTTGGAGGTTGATTTAGGTGG-3'; 10 Wild type p15 5'-TCTGGCCGCAGGGTGCG-3'; 11 5'-CCGGCCGCTCGGCCACT-3'; 12 Methylated p15 5'-AACCGCAAAATACGAACGC-3'; 13 5'-TCGGTCGTTCGGTTATTGTACG-3'; 14 Unmethylated p15 5'-AACCACAAAATACAAACACATCACA-3; 15 5'-TTGGTTGTTTGGTTATTGTATGG-3'; 16 Methylated VHL 5'-GCGTACGCAAAAAAATCCTCCA-3'; 17 5'-TTCGCGGCGTTCGGTTC-3'; 18 Unmethylated VHL 5'-ACATACACAAAAAAATCCTCCAAC-3'; 19 5'-TTTGTGGTGTTTGGTTTGGG-3'; 20 Methylated E-cadherin 5'-ACGCGATAACCCTCTAACCTAA-3'; 21 5'-GTCGGTAGGTGAATTTTTAGTTA-3'; 22 Unmethylated E-cadherin 5'-ACAATAACCCTCTAACCTAAAATTA-3'; 23 5'-TGTGTTGTTGATTGGTTGTG-3'; 24 Methylated Androgen Receptor 5'-GCGACCTCTAAATACCTAAAACCC-3'; 25 5'-CGTAGAGGTTTTATAGGTTATTTGGA-3'; 26 Unmethylated Androgen Receptor 5'-ACAACCTCTAAATACCTAAAACCC-3'; 27 5'-TGTAGAGGTTTTATAGGTTATTTGGT-3'; 28 Methylated Estrogen Receptor 5'-GACGAACTTACTACTATCCAAATACAC-3'; 29 51-TTTACGGTTAGATCGGTTTTTTTTACG-3'; 30 Unmethylated Estrogen Receptor 5'-AACAAACTTACTACTATCCAAATACACC-3'; 31 5'-TGGTTAGATTGGTTTTTTTTATGG-3'; 32 Methylated MDGI 5'-GCCCCCGACTCCCGAAATAAA-3'; 33 5'-CGTCGTCGGAGTTTTTGTACGTT-3'; 34 Unmethylated MDGI 5'-ACCCCCAACTCCCAAAATAAAAAA-3'; 35 5'-TGTTGTTGGAGTTTTTGTATGTTT-3'; 36 Methylated GSTp 5'-GACGACCGCTACACCCCGAA-3'; 37 5'-CGTCGTGATTTTAGTATTGGGGC-3'; 38 Unmethylated GSTp 5'-AACAACCACTACACCCCAAACATC-3'; 39 5'-TGTTGTGATTTTAGTATTGGGGTGG-3'; 40 Methylated Calcitonin 5'-GCCAACGACTACTCTTATTCCCG-3'; 41 5'-CGTCGTCGTTTTTATAGGGTTTTG-3'; 42 Unmethylated Calcitonin 51-ACCAACAACTACTCTTATTCCCACC-3'; 43 5'-TGTTGTTGTTTTTATAGGGTTTTGG-3'; 44 Methylated HIC-1 5'-GACGCACAACCGACTACGAC-3'; 45 5'-CGGCGTTAGGGCGGGTATC-3'; 46 Unmethylated HIC-1 5'-AACACACAACCAACTACAACCC-31; 47 5'-TGGTGTTAGGGTGGGTATTGTG-3'; 48 Methylated Endothelin 5'-GCGTAACCAAAAAAAATAAATAATATAC-3'; 49 5'-CGCGTTGGTGAGTTATGA-3'; 50 Unmethylated Endothelin 5'-ACATAACCAAAAAAb1ATAAATAATATACAA-3'; 51 5'-TGTGTTGGTGAGTTATGAGTGTTAAG-3'; 52 Methylated TIMP-2 5'-GACCGCGCTACCTTCTACGAATAT-3'; 53 5'-CGCGGGAGGGGTTCGTT-3'; 54 Unmethylated TIMP-2 5'-AACCACACTACCTTCTACAAATATATTTACTA-3'; 55 5'-TGTGGGAGGGGTTTGTTTTG-3'; 56 Methylated MLH1-a 5'-GCGACCCTAATAAAACGTCTACGT-3'; 57 5'-CGCGGGTAGTTACGATGAGG-3'; 58 Unmethylated MLH1-a 5'-ACAACCCTAATAAAFICATCTACATCAAAA-3'; 59 5'-TGTGGGTAGTTATGATGAGGTGGT-3'; 60 Methylated MLH1-b 5'-GAACGACATTTTAACGCCAAAAA-3'; 61 5'-CGGCGGGGGAAGTTATTTA-3'; 62 Unmethylated MLH1-b 5'-AAACAACATTTTAACACCAAAAAAACC-3'; 63 5'-TGGTGGGGGAAGTTATTTAGTGG-3'; 64 Methylated MSH2 5'-GAACGACGTCCGACCACGA-3'; 65 5'-CGGTGTAGTCGAAGGAGACGTTG-3'; 66 Urunethylated MSH2 5'-AAACAACATCCAACCACAACAACC-3'; 67 5'-TGGTGTAGTTGAAGGAGATGTTGTAGTTG-3'; 68 Methylated GFAP 5'-GATACCCGAATACCCCTAACAAC-3'; 69 5'-CGTCGTTTTTACGTTTTTTTAGGG-3'; 70 Unmethylated GFAP 5'-AATACCCAAATACCCCTAACAACA-3' 71 5'-TGTTGTTTTTATGTTTTTTTAGGGGA-3' 72 Methylated TGFbl 5'-GCGAACTACCAAACGAACCCA-3'; 73 5'-CGCGGCGGTTAGGGAGG-3'; 74 Unmethylated TGFbl 5'-ACAAACTACCAAACAAACCCAACC-3'; 75 51-TGTGGTGGTTAGGGAGGTGGG-3'; 76 Methylated TGFb2 5'-GCGCGAAAATATCGTCG-3'; 77 5'-CGCGTTTCGTCGGTTT-3'; 78 Unmethylated TGFb2 5'-ACACAAAAATATCATCACTCCATAC-3'; 79 5'-TGTGTTTTGTTGGTTTTTAGGT-3'; 80 Methylated p130 5'-GACGCTAACCGCCTACAAACA-3'; 81 5'-CGGTCGTTTAGGGGTGCGT-3'; 82 Unmethylated p130 5'-AACACTAACCACCTACAAACACCCA-3'; 83 5'-TGGTTGTTTAGGGGTGTGTTATGTT-3'; 84 Methylated BRCA2 5'-GACTCCGCCTCTACCGC-3'; 85 5'-CGGTTTTTGTTAGTTTATTTCG-3'; 86 Unmethylated BRCA2 5'-AACTCCACCTCTACCACCTAAT-3'; 87 5'-TGGTTTTTGTTAGTTTATTTTGG-3'; 88 Methylated 06-MGMT 5'-GCGCGAAAACGAAACCGA-3'; 89 5'-CGCGTTTCGGATATGTTGGG-3'; 90 Unmethylated 06-MGMT 5'-ACACAAAAACAAAACCAAAACAC-3'; 91 5'-TGTGTTTTGGATATGTTGGGA-3'; 92 Methylated NF1 5'-GAACGTCCCTCAACGCCGTAA-3'; 93 5'-CGTATGCGCGGTAGGTCGTTT-3'; 94 Unmethylated NF1 5'-AAACATCCCTCAACACCATA7IAACTC-3'; 95 5'-TGTATGTGTGGTAGGTTGTTTTTTTTTTT-3'; 96 Methylated NF2 5'-GCGAAACTCAAACCCGAAAC-3'; 97 5'-CGTTTATCGTGAGGATCGTTATTAT-3'; 98 Unmethylated NF2 5'-ACAAAACTCAAACCCAAAACCC-3'; 99 5'-TGTTTATTGTGAGGATTGTTATTATGG-3'; 100 Methylated TSG101 5'-GCTACTAAACTACCCCAAACCGTC-3'; 101 51-CGGTCGTTATGGCGGTGTC-3'; 102 Unmethylated TSG101 5'-ACTACTAAACTACCCCAAACCATCC-3'; 103 5'-TGGTTGTTATGGTGGTGTTGGAG-3'; 104 Exemplary primer pairs included in the invention that hybridize to the above sequences include:
SEQ ID NO:
5'-CAGAGGGTGGGGCGGACCGC-3' and 105 5'-CGGGCCGCGGCCGTGG-3'; 106 5'-TTATTAGAGGGTGGGGCGGATCGC-3' and 107 5'-GACCCCGAACCGCGACCGTAA-3'; 108 5'-TTATTAGAGGGTGGGGTGGATTGT-3' and 109 51-CAACCCCAAACCACAACCATAA-31; 110 5'-TTATTAGAGGGTGGGGCGGATCGC-3' and ill 5-CCACCTAAATCGACCTCCGACCG-3'; 112 5'-TTATTAGAGGGTGGGGTGGATTGT-3' and 113 5'-CCACCTAAATCAACCTCCAACCA-3'; 114 5'-CGCACCCTGCGGCCAGA-3' and 115 5'-AGTGGCCGAGCGGCCGG-3'; 116 5'-GCGTTCGTATTTTGCGGTT-3' and 117 5'-CGTACAATAACCGAACGACCGA-3'; 118 WO 97/46705 PCTlUS97/09533 51=TGTGATGTGTTTGTATTTTGTGGTT-3' and 119 5'-CCATACAATAACCAAACAACCAA-3'; 120 5'-TGGAGGATTTTTTTGCGTACGC-3' and 121 51-GAACCGAACGCCGCGAA-3'; 122 5'-GTTGGAGGATTTTTTTGTGTATGT-3' and 123 51-CCCAAACCAAACACCACAAA-31; 124 5'-TTAGGTTAGAGGGTTATCGCGT-3' and 125 5'-TAACTAAAAATTCACCTACCGAC-3'; 126 5'-TAATTTTAGGTTAGAGGGTTATTGT-3' and 127 5'-CACAACCAATCAACAACACA-3' 128 5'GGGTTTTAGGTATTTAGAGGTCGC-3' and 129 5'ACCAAATAACCTATAAAACCTCTACG-3' 130 5'GGGTTTTAGGTATTTAGAGGTTGT-3' and 131 5'ACCAAATAACCTATAAAACCTCTACA-3' 132 5'GTGTATTTGGATAGTAGTAAGTTCGTC-3' and 133 5'CGTAAAAAAAACCGATCTAACCGTAAA-3' 134 5'GGTGTATTTGGATAGTAGTAAGTTTGTT-3' and 135 5'CCATAAAAAAAACCAATCTAACCA-3' 136 5'TTTATTTCGGGAGTCGGGGGC-3' and 137 5'AACGTACAAAAACTCCGACGACG-3' 138 5'TTTTTTATTTTGGGAGTTGGGGGT-3' and 139 5'AAACATACAAAAI;CTCCAACAACA-3' 140 5'TTCGGGGTGTAGCGGTCGTC-3' and 141 5'GCCCCAATACTAAAATCACGACG-3' 142 5'GATGTTTGGGGTGTAGTGGTTGTT-3' and 143 5'CCACCCCAATACTAAAATCACAACA-3' 144 5'CGGGAATAAGAGTAGTCGTTGGC-3' and 145 5'CAAAACCCTATAAAAACGACGACG-3' 146 5'GGTGGGAATAAGAGTAGTTGTTGGT-3' and 147 5'CCAAAACCCTATAAAAACAACAACA-3' 148 5'GTCGTAGTCGGTTGTGCGTC-3' and 149 5'GATACCCGCCCTAACGCCG-3' 150 5'GGGTTGTAGTTGGTTGTGTGTT-3' and 151 5'CACAATACCCACCCTAACACCA-3' 152 5'GTATATTATTTATTTTTTTTGGTTACGC-3' and 153 5'TCATAACTCGCCAACGCG-3' 154 5'TTGTATATTATTTATTTTTTTTGGTTATGT-3' and 155 5'CTTAACACTCATAACTCACCAACACA-3' 156 5'ATATTCGTAGAAGGTAGCGCGGTC-3' and 157 5'AACGAACCCCTCCCGCG-3' 158 5'TAGTAAATATATTTGTAGAAGGTAGTGTGGTT-3' and 159 5'CAAAACAAACCCCTCCCACA-3' 160 5'ACGTAGACGTTTTATTAGGGTCGC-3' and 161 5'CCTCATCGTAACTACCCGCG-3' 162 5'TTTTGATGTAGATGTTTTATTAGGGTTGT-3' and 163 5'ACCACCTCATCATAACTACCCACA-3' 164 5'TTTTTGGCGTTAAAATGTCGTTC-3' and 165 5'TAAATAACTTCCCCCGCCG-3' 166 5'GGTTTTTTTGGTGTTAAAATGTTGTTi-3' and 167 5'CCACTAAATAACTTCCCCCACCA-3' 168 5'TCGTGGTCGGACGTCGTTC-3' and 169 5'CAACGTCTCCTTCGACTACACCG-3' 170 5'GGTTGTTGTGGTTGGATGTTGTTT-3' and 171 5'CAACTACAACATCTCCTTCAACTACACCA-3' 172 S'GTTGTTAGGGGTATTCGGGTATC-3' and 173 5'CCCTP.AAAAAACGTAAAAACGACG-3' 174 5'TGTTGTTAGGGGTATTTGGGTATT-3' and 175 5'TCCCCTAAP.AAAACATAAAAACAACA-3' 176 5'TGGGTTCGTTTGGTAGTTCGC-3' and 177 5'CCTCCCTAACCGCCGCG-3' 178 5'GGTTGGGTTTGTTTGGTAGTTTGT-3' and 179 5'CCCACCTCCCTAACCACCACA-3' 180 5'CGACGATATTTTCGCGC-3' and 181 5'AAACCGACGAAACGCG-3' 182 5'GTATGGAGTGATGATATTTTTGTGT-3' and 183 5'ACCTAAAAACCAACAAAACACA-3' 184 5'TGTTTGTAGGCGGTTAGCGTC-3'and 185 5'ACGCACCCCTAAACGACCG-3' 186 5'TGGGTGTTTGTAGGTGGTTAGTGTT 187 5'AACATAACACACCCCTAAACAACCA-3' 188 5'GCGGTAGAGGCGGAGTC-3' and 189 5'CGAAATAAACTAACAAAAACCG-3' 190 5'ATTAGGTGGTAGAGGTGGAGTT-3' and 191 5'CCAAAATAAACTAACAAAAACCA-3' 192 5'TCGGTTTCGTTTTCGCGC-3' and 193 5'CCCAACATATCCGAAACGCG-3' 194 5'GTGTTTTGGTTTTGTTTTTGTGT-3' and 195 5'TCCCAACATATCCAAAACACA-3' 196 5'TTACGGCGTTGAGGGACGTTC-3' and 197 5'AAACGACCTACCGCGCATACG-3' 198 5'GAGTTTTATGGTGTTGAGGGATGTTT-3' and 199 5' CAACCTACCACACATACA-3' 200 5'GTTTCGGGTTTGAGTTTCGC-3' and 201 5'ATAATAACGATCCTCACGATAAACG-3' 202.

5'GGGTTTTGGGTTTGAGTTTTGT-3' and 203 5'CCATAATAACAATCCTCACAATAAACA-3' 204 5'GACGGTTTGGGGTAGTTTAGTAGC-3' and 205 5'GACACCGCCATAACGACCG-3' 206 5'GGATGGTTTGGGGTAGTTTAGTAGT-3' and 207 5'CTCCAACACCACCATAACAACCA-3' 208 *Also included are modifications of the above sequences, including SEQ ID NO: 107 having the sequence TCAC at the 5' end giving rise to new SEQ ID
NO:214; SEQ ID NO:107 having the sequence CC added at the 5' end giving rise to new SEQ
ID NO:215; SEQ ID NO:107 having the sequence 5'-TTATTAGAGGGTGGGGCGGATCGC-3'; SEQ ID NO:108 having the sequence 5'-GACCCCGAACCGCGACCGTAA-3'; SEQ ID
NO:110 having the sequence TGG added at the 5' end giving rise to new SEQ ID
NO:216; and SEQ ID NO:111 having the sequence TAC added at the 5' end distinguishing it from SEQ ID
NO:107. All of these modified primers anneal at 65 C.

Typically, the CpG-containing nucleic acid is in the region of the promoter of a structural gene. For example, the promoter region of tumor suppressor genes have been identified as containing methylated CpG island.
The promoter region of tumor suppressor genes, including p16, p15, VHL and E-cadherin, are typically the sequence amplified by PCR in the method of the invention. Other genes that have been shown by MSP as containing methylated CpG neoplastic versus normal tissue include estrogen receptor, MDGI, GST-pi, calcitonin, HIC-1, endothelin B receptor, TIMP-2, 06-MGMT, and MLH1. Genes that were found by MSP to be methylated also include the androgen receptor (e.g., methylated as X chromosome inactivation), GFAP (methylated in some glioma cell lines but also in normal tissue), and MSH2. Other genes in which MSP primer were shown to distinguish between normal unmethylated and methylated DNA include TGF-p1, TGF-(32, p130, BRCA2, NFl, NF2, and TSG101.
Detection and identification of methylated CpG-containing nucleic acid in the specimen may be indicative of a cell proliferative disorder or neoplasia. Such disorders include but are not limited to low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, colon cancer, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma. Identification of methylated CpG status is also useful for detection and diagnosis of genomic imprinting, fragile X syndrome and X-chromosome inactivation.
Using the method of the invention, the TIMP-2 gene was identified as associated with or methylated in neoplastic versus normal tissues.
The method of the invention now provides the basis for a kit useful for the detection of a methylated CpG-containing nucleic acid. The kit includes a carrier means being compartmentalized to receive in close confinement therein one or more containers. For example, a first container contains a reagent which modifies unmethylated cytosine, such as sodium bisulfite. A second container contains primers for amplification of the CpG-containing nucleic acid, for example, primers listed above as SEQ ID
NO:105-208.
The invention also provides a kit for the detection of a methylated CpG-containing nucleic acid, wherein the kit includes: a) a reagent that modifies unmethylated cytosine nucleotides; b) control nucleic acid; c) primers for the amplification of unmethylated CpG-containing nucleic acid; d) primers for the amplification of methylated CpG-containing nucleic acid;
and e) primers for the amplification of control nucleic acid. The kit may further include nucleic acid amplification buffer. Preferably, the reagent that modifies unmethylated cytosine is bisulfite.
The kit of the invention is intended to provide the reagents necessary to perform chemical modification and PCR amplification of DNA samples to determine their methylation status. The primer sets included in the kit include a set that anneals to unmethylated DNA that has undergone a chemical modification; a set that anneals to methylated DNA that has undergone a chemical modification; and a primer set that serves as a control for the efficiency of chemical modification. The control primer set should anneal to any DNA (unmethylated or methylated) that has not undergone chemical methylation.
In the case of incomplete chemical modification (up to about 50%), data interpretation can still proceed.
The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only and are not intended to limit the scope of the invention.

Example 1 DNA and Cell Lines. Genomic DNA was obtained from cell lines, primary tumors and normal tissue as described (Merlo, et al., Nature Medicine, 1:686, 1995; Herman, et al., Cancer Research, 56:722, 1996; Graff, et al., Cancer Research, 55:5195, 1995). The renal carcinoma cell line was kindly provided by Dr. Michael Lehrman of the National Cancer Institute, Bethesda, MD.
Bisulfite Modification. 1 pg of DNA in a volume of 50 pl was denatured by NaOH (final 0.2M) for 10 minutes at 37 C. For samples with nanogram quantities of human DNA, 1pg of salmon sperm DNA (Sigma) was added as carrier prior to modification. 30 pL of lOmM hydroquinone (Sigma) and 520 pL of 3 M sodium bisulfite (Sigma) pH5, both freshly prepared, were added, mixed, and samples were incubated under mineral oil at 50 C for 16 hours.
Modified DNA was purified using the WizardT'" DNA
purification resin according to the manufacturer (Promega), and eluted into 50 pL of water. Modification was completed by NaOH (final 0.3M) treatment for 5 minutes at room temperature, followed by ethanol precipitation.
Genomic Sequencing. Genomic sequencing of bisulfite modified DNA was accomplished using the solid-phase DNA sequencing approach (Myohanen, et al., DNA
Seq., 5:1, 1994). 100 ng of bisulfite modified DNA was amplified with p16 gene specific primer 5'-TTTTTAGAGGATTTGAGGGATAGG-3' (sense) (SEQ ID NO:209) and 5'-CTACCTAATTCCAATTCCCCTACA-3' (anti-sense) (SEQ ID
NO:210). PCR conditions were as follows: 96 C for 3 minutes, 80 C for 3 minutes, 1 U of Taq polymerase (BRL) was added, followed by 35 cycles of 96 C for 20 seconds, 56 C for 20 seconds, 72 C for 90 seconds, followed by 5 minutes at 72 C. The PCR mixture contained 1X buffer (BRL) with 1.5mM MgC12, 20 pmols of each primer and 0.2 mM
dNTPs. To obtain products for sequencing, a second round of PCR was performed with 5 pmols of nested primers. In this reaction, the sense primer, 5'-GTTTTCCCAGTCACGACAGTATTAGGAGGAAGAAAGAGGAG-3' (SEQ
ID NO:211), contains M13-40 sequence (underlined) introduced as a site to initiate sequencing, and the anti-sense primer 5'-TCCAATTCCCCTACAAACTTC-3" (SEQ ID NO:212) is biotinylated to facilitate purification of the product prior to sequencing. PCR was performed as above, for 32 cycles with 2.5 mM MgC12. All primers for genomic sequencing were designed to avoid any CpGs in the sequence. Biotinylated PCR products were purified using streptavidin coated magnetic beads (Dynal AB, Norway), and sequencing reactions performed with SequenaseT"' and M13-40 sequencing primer under conditions specified by the manufacturer (USB).
PCR Amplification. Primer pairs described in Table 1 were purchased from Life Technologies. The PCR mixture contained 1X PCR buffer (16.6 mM ammonium sulfate, 67mM
TRIS pH 8.8, 6.7 mM MgClz, and 10 mM (3-mercaptoethanol) , dNTPs (each at 1.25mM), primers (300 ng/reaction each), and bisulfite-modified DNA (-50ng) or unmodified DNA (50-100ng) in a final volume of 50 uL. PCR specific for unmodified DNA also included 5% dimethylsulfoxide.
Reactions were hot started at 95 C for 5 minutes prior to the addition of 1.25 units of Taq polymerase (BRL).
Amplification was carried out on a Hybaid OmniGene temperature cycler for 35 cycles (30 seconds at 95 C, 30 seconds at the annealing temperature listed in Table 1, and 30 seconds at 72 C), followed by a final 4 minute extension at 72 C. Controls without DNA were performed for each set of PCR reactions. 10 pL of each PCR reaction was directly loaded onto non-denaturing 6-8%

WO 97/46705 PCTl1JS97l09533 polyacrylamide-gels, stained with ethidium bromide, and directly visualized under UV illumination.
Restriction Analysis. 10 pL of the 50 pL PCR
reaction was digested with 10 units of BstUI (New England Biolabs) for 4 hours according to conditions specified by the manufacturer. Restriction digests were ethanol precipitated prior to gel analysis.
Example 2 An initial study was required to validate the strategy for MSP for providing assessment of the methylation status of CpG islands. The p16 tumor suppressor (Merlo, et al., supra; Herman, et al., Cancer Research, 55:4525, 1995; Gonzalez-Zulueta, et al., Cancer Res., 55:4531, 1995,27) which has been documented to have hypermethylation of a 5' CpG island is associated with complete loss of gene expression in many cancer types, was used as an exemplary gene to determine whether the density of methylation, in key regions to be tested, was great enough to facilitate the primer design disclosed herein. Other than for CpG sites located in recognition sequences for methylation-sensitive enzymes, the density of methylation and its correlation to transcriptional silencing had not yet been established. The genomic sequencing technique was therefore employed to explore this relationship.
Figure 1 shows genomic sequencing of p16. The sequence shown has the most 5' region at the bottom of the gel, beginning at +175 in relation to a major transcriptional start site (Hara, et al., Mol. Cell Biol., 16:859, 1996). All cytosines in the unmethylated cell line H249 have been converted to thymidine, while all C's in CpG dinucleotides in the methylated cell H157 remains as C, indicating methylation. ] enclosed a BstUI
site which is at -59 in relation to the transnational start site in Genbank sequence U12818 (Hussussian, et al., Nat. Genet., 8:15, 1994), but which is incorrectly identified as CGCA in sequence X94154 (Hara, et al., supra). This CGCG site represents the 3' location of the sense primer used for p16 MSP.
As has been found for other CpG islands examined in this manner (Myohanen, et al., supra; Park, et al., Mol. Cell Bio1., 14:7975, 1994; Reeben, et al., Gene, 157:325, 1995), the CpG island of p16 was completely unmethylated in those cell lines and normal tissues previously found to be unmethylated by Southern analysis (Fig. 1)(Merlo, et al., supra; Herman, et al., supra).
However, it was extensively methylated in cancer cell lines shown to be inethylated by Southern analysis (Fig.
1). In fact, all cytosines within CpG diziucloetides in this region were completely methylated in the cancers lacking p16 transcription. This marked difference in sequence following bisulfite treatment suggested that the method of the invention for specific amplification of either methylated or unmethylated alleles was useful for identification of inethylation patterns in a DNA sample.
Primers were designed to discriminate between methylated and unmethylated alleles following bisulfite treatment, and to discriminate between DNA modified by bisulfite and that which had not been modified. To accomplish this, primer sequences were chosen for regions containing frequent cytosines (to distinguish unmodified from modified DNA), and CpG pairs near the 3' end of the primers (to provide maximal discrimination in the PCR
reaction between methylated and unmethylated DNA). Since the two strands of DNA are no longer complementary after bisulfite treatment, primers can be designed for either modified strand. For convenience, primers were designed for the sense strand. The fragment of DNA to be amplified was intentionally small, to allow the assessment of methylation patterns in a limited region and to facilitate the application of this technique to samples, such as paraffin blocks, where amplification of larger fragments is not possible. In Table 1, primer sequences are shown for all genes tested, emphasizing the differences in sequence between the three types of DNA
which are exploited for the specificity of MSP. The multiple mismatches in these primers which are specific for these different types of DNA suggest that each primer set should provide amplification only from the intended template.
The primers designed for p16 were tested with DNA
from cancer cell lines and normal tissues for which the methylation status had previously been defined by Southern analysis (Merlo, et al., supra; Herman, et al., s upra ) .
Figure 2, panels A-D, show polyacrylamide gels with the Methylation Specific PCR products of p16. Primer sets used for amplification are designated as unmethylated (U), methylated (M), or unmodified/wild-type (W).* designates the molecular weight marker pBR322-Mspl digest. Panel A shows amplification of bisulfite-treated DNA from cancer cell lines and normal lymphocytes, and untreated DNA (from cell line H249). Panel B shows mixing of various amount of H157 DNA with 1 pg of H249 DNA prior to bisulfite treatment to assess the detection sensitivity of MSP for methylated alleles. Modified DNA
from a primary lung cancer sample and normal lung are also shown. Panel C shows amplification with the p16-U2 (U) primers, and p16-M2 (M) described in Table 1. Panel D
shows the amplified p16 products of panel C restricted with BstUI(+) or not restricted (-).
In all cases, the primer set used confirmed the methylation status determined by Southern analysis. For example, lung cancer cell lines U1752 and H157, as well other cell lines methylated at p16, amplified only with the methylated primers (Fig. 2, panel A). DNA from normal tissues (lymphocytes, lung, kidney, breast, and colon) and the unmethylated lung cancer cell lines H209 and H249, amplified only with unmethylated primers (examples in Fig 2, panel A). PCR with these primers could be performed with or without 5% DMSO. DNA not treated with bisulfite (unmodified) failed to amplify with either set of methylated or unmethylated specific primers, but readily amplified with primers specific for the sequence prior to modification (Fig. 2, panel A). DNA from the cell line H157 after bisulfite treatment also produced a weaker amplification with unmodified primers, suggesting an incomplete bisulfite reaction. However, this unmodified DNA, unlike partially restricted DNA in previous PCR assays relying on methylation sensitive restriction enzymes, is not recognized by the primers specific for methylated DNA. It therefore does not provide a false positive result or interfere with the ability to distinguish methylated from unmethylated alleles.
The sensitivity of MSP for detection of methylated p16 alleles was assessed. DNA from methylated cell lines was mixed with unmethylated DNA prior to bisulfite treatment. 0.1% of methylated DNA (approximately 50 pg) was consistently detected in an otherwise unmethylated sample (Fig. 2, panel B). The sensitivity limit for the WO 97/46705 PCTlUS97/09533 amount of input DNA was determined to be as little as 1 ng of human DNA, mixed with salmon sperm DNA as a carrier detectable by MSP.
Fresh human tumor samples often contain normal and tumor tissue, making the detection of changes specific for the tumor difficult. However, the sensitivity of MSP
suggests it would be useful for primary tumors as well, allowing for detection of aberrantly methylated alleles even if they contribute relatively little to the overall DNA in a sample. In each case, while normal tissues were completely unmethylated, tumors determined to be methylated at p16 by Southern analysis also contained methylated DNA detected by MSP, in addition to some unmethylated alleles (examples in Fig. 2, panel B). DNA
from paraffin-embedded tumors was also used, and allowed the detection of methylated and unmethylated alleles in these samples (Fig. 2, panel B). To confirm that these results were not unique to this primer set, a second downstream primer for p16 was used which would amplify a slightly larger fragment (Table 1). This second set of primers reproduced the results described above (Fig 2, panel C), confirming the methylation status defined by Southern blot analysis.
To further verify the specificity of the primers for the methylated alleles and to check specific cytosines for methylation within the region amplified, the differences in sequence between methylated/modified DNA and unmethylated/modified DNA were utilized.
Specifically, the BstUI recognition site, CGCG, will remain CGCG if both C's are methylated after bisulfite treatment and amplification, but will become TGTG if unmethylated. Digestion of the amplified products with Bst UI distinguishes these two products. Restriction of p16 amplified products illustrates this. Only unmodified products and methylated/modified products, both of which retain the CGCG site, were cleaved by Bstill, while products amplified with uninethylated/modified primers failed to be cleaved (Fig. 2, panel D).
The primer sets discussed above were designed to discriminate heavily methylated CpG islands from unmethylated alleles. To do this, both the upper (sense) and lower (antisense) primers contained CpG sites which could produce methylation-dependent sequence differences after bisulfite treatment. MSP might be employed to examine more regional aspects of CpG island methylation.
To examine this, methylation-dependent differences in the sequence of just one primer was tested to determine whether it would still allow discrimination between unmethylated and methylated p16 alleles. The antisense primer used for genomic sequencing, 51-CTACCTAATTCCAATTCCCCTACA-3' (SEQ ID NO:213), was also used as the antisense primer, since the region recognized by the primer contains no CpG sites, and was paired with either a methylated or unmethylated sense primer (Table 1). Amplification of the 313 bp PCR product only occurred with the unmethylated sense primer in H209 and H249 (unmethylated by Southern) and the methylated sense primer in H157 and U1752 (methylated by Southern), indicating that methylation of CpG sites within a defined region can be recognized by specific primers and distinguish between methylated and unmethylated alleles (Fig. 2, panel E). Panel E shows results of testing for regional methylation of CpG islands with MSP, using sense primers p16-U2 (U) and p16-M2 (M), which are methylation specific, and an antisense primer which is not methylation specific.
Example 3 The above experiments with pi6 were extended to include 3 other genes transcriptionally silenced in human cancers by aberrant hypermethylation of 5' CpG islands.
Figure 3, panels A-E, show polyacrylamide gels of MSP products from analysis of several genes. Primer sets used for amplification are not designated as unmethylated (U), methylated (M), or unmodified/wild-type (W). *
designates the molecular weight marker pBR322-Mspl digest and ** designates the 123bp molecular weight marker. All DNA samples were bisulfite treated except those designated untreated. Panel A shows the results from MSP
for p15. Panel B shows the p15 products restricted with BstUI (+) or not restricted (-). Panel C shows the products of MSP for VHL. Panel D shows the VHL products restricted with BstUI(+) or not restricted (-). Panel E
shows the products of MSP for E-cadherin.
The cyclin-dependent kinase inhibitor p15 is aberrantly methylated in many leukemic cell lines and primary leukemias (Herman, et al., supra). For p15, MSP
again verified the methylation status determined by Southern analysis. Thus, normal lymphocytes and cancer cell lines SW48 and U1752, all unmethylated by Southern analysis (Herman, et al., supra), only amplified with the unmethylated set of primers, while the lung cancer cell line H1618 and leukemia cell line KG1A amplified only with the methylated set of primers (Fig. 3, panel A), consistent with previous Southern analysis results (Herman, et al., supra). The cell line Raji produced a strong PCR product with methylated primers and a weaker band with unmethylated primers. This was the same result for methylation obtained previously by Southern analysis (Herman, et al., supra). Non-cultured leukemia samples, like the primary tumors studied for p16, had amplification with the methylated primer set as well as the unmethylated set. This heterogeneity also matched Southern analysis (Herman, et al., supra). Again, as for p16, differential modification of BstUI restriction sites in the amplified product of p15 was used to verify the specific amplification by MSP (Fig. 3, panel B).
Amplified products using methylated primer sets from cell lines H1618 and Raji or unmodified primer sets, were completely cleaved by BstUI, while unmethylated amplified products did not cleave. Primary AML samples, which again only demonstrated cleavage in the methylated product, had less complete cleavage. This suggests a heterogeneity in methylation, arising because in some alleles, many CpG
sites within the primer sequences area are methylated enough to allow the methylation specific primers to amplify this region, while other CpG sites are not completely methylated.
Aberrant CpG island promoter region methylation is associated with inactivation of the VHL tumor suppressor gene in approximately 20% of clear renal carcinomas (Herman, et al., Proc. Natl. Acad. Sci. USA, 91:9700, 1994). This event, like mutations for VHL (Gnarra, et al., Nature Genetics, 7:85, 1994), is restricted to clear renal cancers (Herman, et al., supra). Primers designed for the VHL sequence were used to study DNA from the renal cell cancer line RFX393 which is methylated at VHL
by Southern analysis, and the lung cancer cell line U1752 which is unmethylated at this locus (Herman, et al., supra). In each case, the methylation status of VHL
determined by MSP confirmed that found by Southern analysis (Fig. 3, panel C), and BstUI restriction site WO 97/46705 PCTlUS97/09533 analysis validated the PCR product specificity (Fig. 3, panel D).
The expression of the invasion/metastasis suppressor gene, E-cadherin, is often silenced by aberrant methylation of the 5' promoter in breast, prostate, and many other carcinomas (Graff, et al., supra; Yoshira, et a1 ., Proc. Nat1. Acad. Sci. USA, 92:7416, 1995). Primers were designed for the E-cadherin promoter region to test the use of MSP for this gene. In each case, MSP analysis paralleled Southern blot analysis for the methylation status of the gene (Graff, et al., supra). The breast cancer cell lines MDA-MB-231, HS578t, and the prostate cancer cell lines DuPro and TSUPrI, all heavily methylated by Southern, displayed prominent methylation. MCF7, T47D, PC-3, and LNCaP, all unmethylated by Southern, showed no evidence for methylation in the sensitive MSP assay (Fig. 3, panel E).
MSP analysis revealed the presence of unmethylated alleles in Hs578t, TSUPrI and DuPro consistent with a low percentage of unmethylated alleles in these cell lines previously detected by Southern analysis (Graff, et al., supra). BstUI restriction analysis again confirmed the specificity of the PCR amplification.

-m ~
U 0 O rl .-t r- 1-0 eo LO C) V4 W r- lo l0 cD 0 lD o V* .-1 -1 o 1-1 C7 0 r-1 .-1 r--t r-1 r-i V v (M -I --I N N
W + + + + +
-!- -F -F 1 1 +
O b V
N N m O ~y .fiQi yEy~ =-1 (IS =

W y 0 kV=. jff ~~ t='1 ~ W0 U U C.~ U t.) CJ U ~~ U U U ~' w F
O O O O O O O O O O O
Lf1 n tf) LO C) tl) CD O O O C~ n') ~~ ,~.
41 ~D lO ti0 lD lO CO l0 ~.O l0 lD ~.f) Lry W C RI
q M 1t _ y m U
N ~+ C. C) -1 vcr r- Om c m tS) tO tH
=.=1 .N C t!) m m M n') ct= tr) LO l0 rt 1-cn -I .--i r--i m v ~
W C Ea :" fjS
L -I.I U

HI KC v UI U UI I x'o x ~) .~
Ul ~ U1 a aHi r.~D ~ I~ ~ ~ ~I uI U ~I U ~ p u x 1~
~H7 cu7f I~ 0 U <
~I (hl I U y q $4 U U C7I I C7 U U H v 4{ uuu w d rl ~ CU7 U H H CUh CU7I H FU+ a n m RS N
m _ U ~ ~ w GL
U
cf) v~! m U U U U U 0 U ~
I I 'g U {, =rl 1 C7 U U D H
~ U U rs, y~ ,o KC E~ H
o 0 c91 U 0 UU C ~U
d a 8 tl , -H U U U U ~[,' U U 1 U H U
Ch ,yJ v co Ra~~i .- N ~-I
r ~ n ~ V%D4 Al ~ UI HI UI HI H HI CH.7I ~
44 HU I HI HI HI HI tU7l FCI CHJ ~I ~ a~ e U r-( FC FC FC < CD UI H UI H 3 ~ U 0 C7 0 t7 EI H a C7 C7 H '~~ u] S-I
C7 C7 0 CD 0 E=1 H H HI UI (7 O
or) U U) HI U! HI FC U H C7 C9 H (9 C7 C7 H UI H ~ (.7 'u +~ C7 C7 C7 t~ r~ UI ~C C7 H H
U) U' 0 U' C7 C7 U U' H E-i El El tq N U]
~ Ic U t7 C7 L7 Ch U H C7 H H 0 FC 5. -rl !=1 H C7 E-E H H H C.~3 H HI H H C7 H ~C~" 44 U
~ N C7 c7 C7 0 Ch C7 H H E- E-1 C7 H ~ SZ, -i ~
1~ q C7 CD C7 U C7 U H H H H r.C 0 . O 2{ -ri -,-1 =~-! CD t'J C~ 00C7 9C7 H FC C7 C7 ~..i LI El FC +~C FC H H HI H 0 FC r.~ a+ o ~ W CL N
i~ '= CD 0 C7 C~ U t9 {.7 FC t7 H H y~ u ~
,--1 c7 FC FC ~C FC U UI Hf C~ KC H H
~ C7 Ch C7 H a0 ~i H H H H ~ H C7 FC 0 U' H U -C Ql 4-I C) U q - C7 r~ FC ~C FC U C7 HI C7 H r~ r~ u a k .6~ -rl -1 a) v r.C EI H H H C7 UI C? U H H FC u~ v O
t~ U H H H H U C7 HI H 0 H H .01, ~ "-r-I a) QUj p m R, '.~.~
v (D
v b . Sa 1 ,_..~ Q) I N U) 1 I i I 1 ~{ 4,) CY
=s~ .i 41 10 1.o lD co 10 Ln in Ln a a ~ ro ~s w W ai 01 O P. i~, Li, a R, > W W N a ~ ri m ~ V
aj L[1 O LO
p '-1 r"f N

SUBSTITUTE SHEET (RULE 26) ~ ~ rn C~! C=> 00 cv} M

N

~ N N cq ~ O O "Izr O"Iti = t~ l~
=a N N [~ 00 00 h tn C5 C >C a >G >C X

U U C~ C~ U U C.~ U U U C~ U
n n ~ c o 0 0 0 0 0 0 -n W) tn -n c~ a n o_ _o .a .n ,.c .o a n .sQ n M a~. N N !o C>N ~ en cz H bvA cz co .5 U ~

U U U bA V CO D Ubb Uy U
aS cz cc3 cd Ucc~c~ ~ U " bA U ~ ~ tUC
~ cUC
cG cV cpc~p Cc'G4' U Y a5 ~.~ CO U U ~ [~C ~ ~ C) .5 Ri ~ U U ~ clY N Rt U '-' ca +' V U
-UQ a +cr~ cK ~ ~ CCCCf c~0 U cUC ccc U~ ~c~
y t~C cC ~ ,=~+ bAU U U cc~~i cV W
= U U b4 U m ai U U c~ NU cd u C fd Cd U U ltt at bA U U U N) V'1 In V1 Vl V'1 V'1 ~n tn v'1 tn l(7 ln U -U to bA
b-0 b0 Y -0pqpp to U~ bA Ybq bq bA m bA +' bA ~p .c~ U~ ~M
Y cc~ bA y cC bA
bYU ~pp ~ cbAn ~ cn bA
qp U
bII i bq dq p~p b"0 L Yb.~ f-! U bA ~b'p.
Cy O1J 01I _bA - r bA Utw _bl,l bA OA
lP1 tn N N ul Ul Vn 0 cr_l w z ~ c~ c;~ ~ x in CD
~n -i ~

WO 97/46705 Y'CT/US97/09533 N
O C
N N
~O \D cV N ~ O ~O oo M
N N N N as O CN cq N .N..
~D ~O O~ O
00 00 v~j V~') O O ,d- ~ .-M. .-M.
M M V1 ~!S v'1 Q
V U U U U u U U U U U U U U
n n o 0 0 0 0 0 0 0 kn W) tn ~o ~o ~a ~o ~o ~o lD ~o tn O ,.O N en O
N a, cC
U
U V bD
~ t U C U U ~ '~"i m U
U M ~ ~
bA U CA c~ bUA ~ U v C~ c~U
bD U
~ U U ~ bD U ~ aS
U U U U U ~ U U af ~- V bU4 U
U U V U V W U ft!
bA U U U ~ +=' U ai U cli a7 L) cts U tC U U U cts tU U
03 cc V m w ~ U V V ~,Uj cUC
ui U
w U W C.~ V cU W
0 +.~+ U U U U +-U+ V U
V1 V'1 l!') 4'1 V') t/') v7 V7 In kA v') tP1 I/1 ~A
GD bQ CQ _t ~... bU0 ~q U~ b1} U W Y~ U =t'=' ~

ca cci U bQ
U

I ~ bõ=,~}r! 171 C', ~n eA W '-' pp bA a.+ CfS i3 C~ ,F M Y W A bA
~!1 V'1 Vy ~ N tA V1 V7 -A tn V1 N tn tn Q) N
.~ =-= ~ r~."i '~i x ~ C=wl E~-LO
O
r-1 %~o N
r- r- N l- V' O~ M M
O O O~1 oo ~ O M M 00 ~10 M N
N N N N M M M M N N
N O O
N N N N 00 00 O O ~
~ v'~ M M 'i v N N _ ~ 00 00 X yC ai v~i U U U U U U U U U U U U U U

t- tn v's v'N tn O O O O vl in p Vl V'1 kn N N V1 \O ~O ~D \6 ul In ~O 110 ~y G t]. G S3. fs. f-]. F1. C]. Cl. L]. C1.
~ v1 v'1 ~D N v~ ~ ~ 'cl' O\ M ~ .t]
tn .--~ .--~ 00 00 ttl U
c~s cc cu bA U ~ 0 cu dD co U
cd a3 ca ~y bp ccc~
[~d d0 U m U aJ bA U aV+ bq ~
ca tUG cd U m c ~C bA V.+ U c~ V
~ U
0.i ce U bU ~
m Y cci U
bD U ~ a+ c~0 U U
t4 cd Cd co cu co c m ~ cVV a0 U
U cV ct CO D U t* bD U U w cC a.~ U 1zf ~.V..
~
cd cC c3 ta U U U -cd cd -cci U b4 N IA In V") In ~n N ~!1 V'1 ~!1 kn N
aJ
~A p~p Y bYA cOA
bD y ~p U ~ cd bA ~ W Upp ~ ~ bUA ~ ~ oA ~ ~ bA
i}bA
00 b ~p }~-!
pp p.~ oD CU GD Cp ~+
ap bbAA . 0 60 b4 ~p dq ~ ~ GD ~ ~ ~ G ~ ct ~p byA b~A bUA ~ aV+ bA "~~' bA b~'4 b~A bA t~D
V~ ~A t~ ~!1 Vl h V'1 V1 ~A V'1 ~!1 N V~
O
~D ~D ~D

Cw7 ~ ~ ci w d H p.. o0 o z z LO o Ln Example 4 Indirect in situ p16 Methylation. Indirect in situ PCR (indirect IS-PCR) describes a technique whereby the amplicon is produced by thermal cycling without label incorporation. At the end of the cycling reaction, the amplified product is detected by standard in situ hybridization using a labeled probe.
Sample Preparat3.on and Pretreatment. Paraffin-embedded formalin fixed HN12 cells were deparaffinized in xylene for 5 minutes, followed by two 5 minute rinses in 100% ethanol. Slides were air dried, and then treated with Proteinase K(10/-tg/ml in 50mM Tris) for 30 minutes at 37 C under a coverslip. Slides were rinsed in distilled water and placed in 0.2N NaOH for 10 minutes at 37 C, then placed in 3M Sodium bisulfite containing hydroxyquinone.
The solution was layered with mineral oil and left at 50 C
for 16 hours. The oil was removed, and the slides were rinsed in water and placed in 0.3M NaOH for 5 minutes at room temperature. Slides were then dehydrated in 70%, 80%, and 100% ethanol and air dried.
Indirect IS-PCR Protocol. The PCR mixture contained 1xPCR buffer (16.6mM ammonium sulfate/67mM
Tris, pH 8.8/6.7mM MgCl2/10mM 2-mercaptoethanol), dNTPs (2.5 lambda of 25mM mix), 300ng of each primer, and 2.5 Units of Taq Polymerase per 50,u1 reaction. This mixture was "hot started" at 95 C for 5 minutes, then added directly to the slides which were prewarmed to 80 C with a GeneComb in place. PCR was performed on a Hybaid Omnigene Cycler with an in situ module. Thirty cycles of 90 C for 30 seconds, 58 C for 45 seconds, and 70 C for 45 seconds were performed with a calibration number of 50.
After the PCR, slides were immediately rinsed once in distilled water, followed by dehydration in 70%, 80%, and 100% ethanol and air dried.
Indirect IS-PCR In Situ Hybridization and Fluorescence Detection. Following the PCR, the specimen was fixed briefly to maintain the localization of the PCR
product. This was accomplished by fixing the sections in 100% ethanol for 15 minutes and then allowing them to air dry before application of the probe. A methylated p16 PCR product was generated and labeled with digoxigenin, and used as a labeled probe for in situ hybridization.
The digoxigenin labeled probe was suspended in a hybridization buffer containing 2xSSC/10% Dextran Sulfate/50% Formamide for a final concentration of lOng/ul. 10.0%cl(100.Ong of probe) of the hybridization mixture was placed on each sample, covered with a glass coverslip and sealed with rubber cement_ The cell preparations were then incubated at 95 C for 5 minutes and hybridized at 37 C overnight in a humidified chamber.
Following hybridization, the HN12 samples were post-washed in 2xSSC (salt sodium citrate) at room temperature for five minutes and placed in 1xPBD
(phosphate buffered detergent) at room temperature prior to immunological detections.
All hybridized HN12 cell samples were immunocytochemically stained with fluorescein labeled avidin (Vector Laboratories, CA). Sixty microliters of detection reagent, consisting of fluorescein labeled avidin (10ug/ml), 1XPBS, 5% powdered dry milk, and 0.02%
sodium azide was applied to the slide under a plastic coverslip and incubated at 37 C for five minutes in a humidified chamber. The slides were washed in 1XPBD
several times and counterstained with propidium iodide (0.3ug/ml) in antifade solution.
For fluorescence microscopy, a Zeiss Axiophot 20 epi-fluorescence microscope (Zeiss, West Germany) equipped with a 100-Watt mercury-arc lamp, a 100X
Plan-Neofluar oil immersion objective (Zeiss, West Germany), a Zeiss MC-100 camera (Zeiss, West Germany), and the appropriate filter sets for fluorescein (FITC)/PI
fluorescence (Chroma, VT) were utilized. Image analysis and record keeping was performed using an OIS (Oncor Instrument Systems) 3CCD Cooled Camera System and OIS
2.01 Image Analysis Software.
The negative PCR control HN12 cell sample was processed using an initial bisulfite reaction to modify the DNA, followed by PCR amplification using primers specific for the methylated DNA of the promoter regions of the p16 gene, and in situ hybridization. The negative control displayed no visible signal as expected, since the PCR reaction was incomplete.
P16 methylated HN12 cells were subjected to the bisulfite modification, PCR amplification using primers specific for the methylated DNA of the promoter regions of the p16 gene, and in situ hybridization using the labeled probe. Fluorescent signals specific for the amplified, localized product of the methylated p16 promoter regions were visible in the cells.
P16 methylated HN12 cells were subjected to the bisulfite modification, PCR amplification using primers specific for the unmethylated DNA of the promoter regions of the p16 gene, and in situ hybridization using the labeled probe. No fluorescent signals were visible in the cells.
Exam-ple 5 Testing the Use of MSP for Methylation Changes in Sputum Samples. MSP has been tested to detect methylation changes in DNA from sputum samples. The samples tested included the primers for p16 (Table 1; SEQ
ID NOS:105-110) and DNA extracted from sputum samples from two patients known to have lung cancer. The unmethylated alleles for p16 were detected, however, methylated alleles were not detected. It appears that since the MSP worked with the non-methylated alleles, that the patient's tumors did not have methylated p16.
To test this hypothesis, one sputum sample was spiked with cells from the established lung cancer cell line Calu 3, which has a hypermethylated p16 gene. These p16 methylated alleles were easily detected in this mixed DNA.
Exam-ple 6 MSP for detection of hMLHl and hMSH2 hypermethylati.on. The hMLH1 and hMSH2 genes encode for mismatch repair proteins, and mutations in each can cause inherited forms of colon cancer marked by microsatellite instability. Some 20% of patients with non-inherited colon cancer also have tumors with the microsatellite instability phenotype. The precise mechanism causing these latter tumors is not clear. Kane et al. (Cancer Research, 57:808, 1997) have reported in small series, that tumors from patients with the sporadic form of colon cancers with microsatellite instability have hypermethylation of the promoter of the hMLH1 gene. MSP, employing the primer set and conditions for hMSH2 and hMLH1 (Table 2; SEQ ID NO:161-172), was used to follow up on this observation in a larger series of tumors. In some 14 patients with such tumors, 85% have hypermethylation of hMLHI while only 5% of 21 colon tumors without microsatellite instability show this change. No hypermethylation of hMSH2 was seen in either group. The data indicate that 15% or so of all patients with colon cancer, who are known to have tumors with microsatellite instability, have hypermethylation of the hMLH1 gene in tumor DNA, and that transcriptional silencing associated with this change is the cause of the genetic instability in this setting.
Example 7 MSP studies of the Tissue Inhibitor of Metalloproteinase II (TIMP 2) gene. TIMP2 is a member of a family of metalloproteinase inhibitors which are necessary to limit the invasive potential of multiple cell types. Using the MSP primers and conditions for this gene (Table 2; SEQ ID NOS:157-160), hypermethylation of the TIMP2 promoter was found in approximately 50% of primary colon cancer. This change, and the associated loss of expression for this gene, could be a key factor in increasing the invasive potential for the colon cancers involved.

Examle 8 MSP Studies of the TGF-beta Receptor I and II
genes. MSP primers and conditions previously provided (Table 2; SEQ ID NOS:177-184) have been successfully employed for TGF-beta receptor I and II genes, and no evidence for promoter hypermethylation in tumors has been found to date.

Although the invention has been described with reference to the presently preferred embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

-59.1-SEQUENCE LISTING
(1) GENERAL INFORMATION:

(i) APPLICANT: The Johns Hopkins University School of Medicine (ii) TITLE OF INVENTION: Methylation Specific Detection (iii) NUMBER OF SEQUENCES: 216 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: MBM & Co.
(B) STREET: P.O. Box 809, Station B
(C) CITY: Ottawa (D) STATE: Ontario (E) COUNTRY: Canada (F) ZIP: K1P 5P9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBMT"' PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOSTM
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,257,104 (B):FILING DATE: June 3, 1997 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/835,728 (B) FILING DATE: April 11, 1997 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/656,716 (B) FILING DATE: June 03, 1996, (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Swain, Margaret (B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 198-230 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 613/567-0762 (B) TELEFAX: 613/563-7671 (2) INFORMATION FOR SEQ ID NO:l:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid -59.2-(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

-59.3-(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.4-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:17 base pairs (B) TYPE: nucleic acid -59.5-(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

-59.6-(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

(2) INFORMATION FOR SEQ ID N0:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

.~ .

-59.7-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single -59.8-(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

(2) INFORMATION FOR SEQ ID NO:27:

-59.9-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

-59.10-(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.11-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

-59.12-(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.13-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

-59.14-(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.15-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

ACATAACCAA AAA.AAATAAA TAATATACAA 30 (2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

-59.16-(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.17-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

-59.18-(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.19-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

-59.20-(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.21-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single -59.22-(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

-59.23-(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear -59.24-(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

-59.25-(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear -59.26-(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

-59.27-(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear -59.28-(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

-59.29-(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single -59.30-(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.31-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

-59.32-(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear -59.33-(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

-59.34-(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

(2) INFORMATION FOR SEQ ID NO:118:

-59.35-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

(2) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHANACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

(2) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.36-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

-- - --59.37-(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

,~..,~..~

-59.38-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:
-..~.

-59.39-(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.40-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

-59.41-(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

-59.42-(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid -59,44=

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid -59.45-(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

-59.46-(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid -59.47-(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

(2) INFORMATION FOR SEQ ID NO:163:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

-59.48-(2) INFORMATION FOR SEQ ID NO:164:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid -59.49-(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

(2) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

(2) INFORMATION FOR SEQ ID NO:169:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

(2) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

-59.50-(2) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

(2) INFORMATION FOR SEQ ID NO:172:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

(2) INFORMATION FOR SEQ ID NO:173:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs -59.51-(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

-59.52-(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs -59.53-(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.54-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:

-59.55-(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.56-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

(2) INFORMATION FOR SEQ ID NO:195:

-59.57-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.58-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

-59.59-(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

-59.60-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

(2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

(2) INFORMATION FOR SEQ ID NO:207:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

(2) INFORMATION FOR SEQ ID NO:208:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

(2) INFORMATION FOR SEQ ID NO:209:

(i) SEQUENCE CHARACTERISTICS:

-59.61-(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

(2) INFORMATION FOR SEQ ID NO:210:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

(2) INFORMATION FOR SEQ ID NO:211:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

(2) INFORMATION FOR SEQ ID NO:212:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

.~_ .~ ~

-59.62-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

(2) INFORMATION FOR SEQ ID NO:213:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

(2) INFORMATION FOR SEQ ID NO:214:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

(2) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

-59.63-(2) INFORMATION FOR SEQ ID NO:216:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

Claims (28)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for detecting a methylated CpG-containing nucleic acid comprising:

(a) contacting a nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, (b) amplifying the CpG-containing nucleic acid in the specimen by means of specific oligonucleotide primers, which are designed to specifically recognize the CpG-sites, wherein the oligonucleotide primers distinguish between methylated nucleic acid treated with said agent and non-methylated nucleic acid treated with said agent, and (c) detecting the methylated nucleic acid.
2. The method of claim 1, wherein the amplifying step is the polymerase chain reaction (PCR).
3. The method of claim 1 or 2, wherein the modifying agent is bisulfite.
4. The method of any one of claims 1 to 3, wherein the cytosine is modified to uracil.
5. The method of any one of claims 1 to 4, further comprising contacting the nucleic acid with a methylation sensitive restriction endonuclease.
6. The method of claim 5, wherein the restriction endonuclease is selected from the group consisting of MspI, HpaII, BssHII, BstUI and NotI.
7. The method of any one of claims 1 to 6, wherein the CpG-containing nucleic acid is in a promoter region.
8. The method of claim 7, wherein the promoter is a tumor suppressor gene promoter.
9. The method of claim 8, wherein the tumor suppressor gene is selected from the group consisting of p16, p15, E-cadherin, and VHL.
10. The method of any one of claims 1 to 6, wherein the CpG-containing nucleic acid encodes a protein selected from the group consisting of androgen receptor, estrogen receptor, TGF-betal, TGF-beta2, p130, BRCA2, NF1, NF2, TSG101, MDGI, GST-pi, calcitonin, HIC-1, endothelin B receptor, TIMP-2, 06-MGMT, MLH1, MSH2, and GFAP.
11. The method of any one of claims 1 to 10, wherein the specimen is selected from the group consisting of brain, colon, urogenital, lung, renal, hematopoietic, breast, thymus, testis, ovarian, and uterine tissue or from the group consisting of serum, urine, saliva, cerebrospinal fluid, sputum, ejaculate, blood, and stool.
12. The method of any one of claims 1 to 11, wherein the presence of methylated CpG-containing nucleic acid in the specimen is indicative of a cell proliferative disorder.
13. The method of claim 12, wherein the disorder is selected from the group consisting of low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, colon cancer, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.
14. The method of any one of claims 1 to 13, wherein the primers hybridize with a target polynucleotide sequence having a sequence selected from the group consisting of SEQ ID NO: 1-103 and SEQ ID NO: 104.
15. The method of any one of claims 1 to 13, wherein the primers are selected from the group consisting of SEQ ID NO: 105-207 and SEQ ID NO: 208.
16. A kit for use in detection of a methylated CpG-containing nucleic acid comprising:
(a) an agent which modifies unmethylated cytosine;
(b) oligonucleotide primers which are designed to specifically recognize CpG-sites, wherein the oligonucleotide primers distinguish between methylated nucleic acid treated with said agent and non-methylated nucleic acid treated with said agent, and amplify said non-methylated nucleic acid; and (c) oligonucleotide primers which are designed to specifically recognize CpG-sites, wherein the oligonucleotide primers distinguish between methylated nucleic acid treated with said agent and non-methylated nucleic acid treated with said agent, and amplify said methylated nucleic acid.
17. The kit of claim 16, wherein the agent is bisulfite.
18. The kit of claim 16 or 17, wherein the cytosine is modified to uracil.
19. A kit for the detection of methylated CpG-containing nucleic acid from a sample comprising:
(a) an agent that modifies unmethylated cytosine nucleotides;
(b) control nucleic acid;
(c) oligonucleotide primers which are designed to specifically recognize CpG-sites, wherein the oligonucleotide primers distinguish between methylated nucleic acid treated with said agent and non-methylated nucleic acid treated with said agent, and amplify said non-methylated nucleic acid;

(d) oligonucleotide primers which are designed to specifically recognize CpG-sites, wherein the oligonucleotide primers distinguish between methylated nucleic acid treated with said agent and non-methylated nucleic acid treated with said agent, and amplify said methylated nucleic acid; and (e) primers for the amplification of control nucleic acid.
20. The kit of claim 19, further comprising nucleic acid amplification buffer.
21. The kit of claim 19 or 20, wherein the agent that modifies unmethylated cytosine is bisulfite.
22. The kit of any one of claims 19 to 21, wherein the cytosine nucleotides are modified to uracil.
23. The kit of any one of claims 16 to 22, wherein the primers hybridize with a target polynucleotide sequence having a sequence selected from the group consisting of SEQ ID NO: 1-103 and SEQ ID NO: 104.
24. The kit of any one of claims 16 to 22, wherein the primers are selected from the group consisting of SEQ ID NO: 105-207 and SEQ ID NO: 208.
25. Oligonucleotide primer pair(s) for detection of a methylated CpG-containing nucleic acid wherein each primer of the primer pair(s) specifically recognizes CpG-sites and hybridizes with a target polynucleotide sequence having a sequence selected from the group consisting of SEQ ID NO: 1-103 and SEQ ID NO: 104, and wherein each oligonucleotide primer pair distinguishes between methylated nucleic acid treated with an agent that modifies unmethylated cytosine nucleotides and non-methylated nucleic acid treated with said agent, and amplifies either said methylated nucleic acid or said non-methylated nucleic acid.
26. The primer pair(s) of claim 25, wherein each primer of the primer pair(s) is selected from the group consisting of SEQ ID NO: 105-207 and SEQ ID NO: 208.
27. The primer pair(s) of claim 25, wherein (a) when the target sequence is SEQ ID NOs:3 and 4, the primer pair is SEQ ID
NOs:107 and 108;

(b) when the target sequence is SEQ ID NOs:5 and 6, the primer pair is SEQ ID
NOs:109 and 110;

(c) when the target sequence is SEQ ID NOs:7 and 8, the primer pair is SEQ ID
NOs:111 and 112;

(d) when the target sequence is SEQ ID NOs:9 and 10, the primer pair is SEQ ID

NOs:113 and 114;

(e) when the target sequence is SEQ ID NOs: 13 and 14, the primer pair is SEQ
ID NOs:117 and 118;

(f) when the target sequence is SEQ ID NOs: 15 and 16, the primer pair is SEQ
ID NOs:119 and 120;

(g) when the target sequence is SEQ ID NOs:17 and 18, the primer pair is SEQ
ID NOs:121 and 122;

(h) when the target sequence is SEQ ID NOs:19 and 20, the primer pair is SEQ
ID NOs:123 and 124;

(i) when the target sequence is SEQ ID NOs:21 and 22, the primer pair is SEQ
ID NOs:125 and 126;

(j) when the target sequence is SEQ ID NOs:23 and 24, the primer pair is SEQ
ID NOs:127 and 128;

(k) when the target sequence is SEQ ID NOs:25 and 26, the primer pair is SEQ
ID NOs:129 and 130;

(l) when the target sequence is SEQ ID NOs:27 and 28, the primer pair is SEQ
ID NOs:131 and 132;

(m)when the target sequence is SEQ ID NOs:29 and 30, the primer pair is SEQ
ID NOs:133 and 134;

(n) when the target sequence is SEQ ID NOs:31 and 32, the primer pair is SEQ
ID NOs:135 and 136;

(o) when the target sequence is SEQ ID NOs:33 and 34, the primer pair is SEQ
ID NOs:137 and 138;

(p) when the target sequence is SEQ ID NOs:35 and 36, the primer pair is SEQ
ID NOs:139 and 140;

(q) when the target sequence is SEQ ID NOs:37 and 38, the primer pair is SEQ
ID NOs:141 and 142;

(r) when the target sequence is SEQ ID NOs:39 and 40, the primer pair is SEQ
ID NOs:143 and 144;

(s) when the target sequence is SEQ ID NOs:41 and 42, the primer pair is SEQ
ID NOs:145 and 146;

(t) when the target sequence is SEQ ID NOs:43 and 44, the primer pair is SEQ
ID NOs:147 and 148;

(u) when the target sequence is SEQ ID NOs:45 and 46, the primer pair is SEQ
ID NOs:149 and 150;

(v) when the target sequence is SEQ ID NOs:47 and 48, the primer pair is SEQ
ID NOs:151 and 152;

(w) when the target sequence is SEQ ID NOs:49 and 50, the primer pair is SEQ
ID NOs:153 and 154;

(x) when the target sequence is SEQ ID NOs:51 and 52, the primer pair is SEQ
ID NOs:155 and 156;

(y) when the target sequence is SEQ ID NOs:53 and 54, the primer pair is SEQ
ID NOs:157 and 158;

(z) when the target sequence is SEQ ID NOs:55 and 56, the primer pair is SEQ
ID NOs:159 and 160;

(aa) when the target sequence is SEQ ID NOs:57 and 58, the primer pair is SEQ ID NOs:161 and 162;

(bb) when the target sequence is SEQ ID NOs:59 and 60, the primer pair is SEQ ID NOs:163 and 164;

(cc) when the target sequence is SEQ ID NOs:61 and 62, the primer pair is SEQ ID NOs:165 and 166;

(dd) when the target sequence is SEQ ID NOs:63 and 64, the primer pair is SEQ ID NOs:167 and 168;

(ee) when the target sequence is SEQ ID NOs:65 and 66, the primer pair is SEQ ID NOs:169 and 170;

(ff) when the target sequence is SEQ ID NOs:67 and 68, the primer pair is SEQ
ID NOs:171 and 172;

(gg) when the target sequence is SEQ ID NOs:69 and 70, the primer pair is SEQ ID NOs:173 and 174;

(hh) when the target sequence is SEQ ID NOs:71 and 72, the primer pair is SEQ ID NOs:175 and 176;

(ii) when the target sequence is SEQ ID NOs:73 and 74, the primer pair is SEQ
ID NOs:177 and 178;

(jj) when the target sequence is SEQ ID NOs:75 and 76, the primer pair is SEQ
ID NOs:179 and 180;

(kk) when the target sequence is SEQ ID NOs:77 and 78, the primer pair is SEQ ID NOs:181 and 182;

(ll) when the target sequence is SEQ ID NOs:79 and 80, the primer pair is SEQ
ID NOs:183 and 184;

(mm) when the target sequence is SEQ ID NOs:81 and 82, the primer pair is SEQ ID NOs:185 and 186;

(nn) when the target sequence is SEQ ID NOs:83 and 84, the primer pair is SEQ ID NOs:187 and 188;

(oo) when the target sequence is SEQ ID NOs:85 and 86, the primer pair is SEQ ID NOs:189 and 190;

(pp) when the target sequence is SEQ ID NOs:87 and 88, the primer pair is SEQ ID NOs:191 and 192;

(qq) when the target sequence is SEQ ID NOs:89 and 90, the primer pair is SEQ ID NOs:193 and 194;

(rr) when the target sequence is SEQ ID NOs:91 and 92, the primer pair is SEQ
ID NOs:195 and 196;

(ss)when the target sequence is SEQ ID NOs:93 and 94, the primer pair is SEQ
ID NOs:197 and 198;

(tt) when the target sequence is SEQ ID NOs:95 and 96, the primer pair is SEQ
ID NOs:199 and 200;

(uu) when the target sequence is SEQ ID NOs:97 and 98, the primer pair is SEQ ID NOs:201 and 202;

(vv) when the target sequence is SEQ ID NOs:99 and 100, the primer pair is SEQ ID NOs:203 and 204;

(ww) when the target sequence is SEQ ID NOs:101 and 102, the primer pair is SEQ ID NOs:205 and 206;

(xx) when the target sequence is SEQ ID NOs:103 and 104, the primer pair is SEQ ID NOs:207 and 208.
28. Use of the kit of any one of claims 16 to 24 in the method of any one of claims 1 to 15.
CA002257104A 1996-06-03 1997-06-03 Methylation specific detection Expired - Lifetime CA2257104C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2612690A CA2612690C (en) 1996-06-03 1997-06-03 Methylation specific detection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/656,716 1996-06-03
US08/656,716 US5786146A (en) 1996-06-03 1996-06-03 Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US08/835,728 US6017704A (en) 1996-06-03 1997-04-11 Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US08/835,728 1997-04-11
PCT/US1997/009533 WO1997046705A1 (en) 1996-06-03 1997-06-03 Methylation specific detection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2612690A Division CA2612690C (en) 1996-06-03 1997-06-03 Methylation specific detection

Publications (2)

Publication Number Publication Date
CA2257104A1 CA2257104A1 (en) 1997-12-11
CA2257104C true CA2257104C (en) 2008-01-29

Family

ID=27097252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257104A Expired - Lifetime CA2257104C (en) 1996-06-03 1997-06-03 Methylation specific detection

Country Status (11)

Country Link
US (2) US6017704A (en)
EP (2) EP0954608B1 (en)
JP (2) JP3612080B2 (en)
AT (1) ATE326549T1 (en)
CA (1) CA2257104C (en)
DE (1) DE69735894T2 (en)
DK (1) DK0954608T3 (en)
ES (1) ES2264165T3 (en)
IL (1) IL127342A (en)
PT (1) PT954608E (en)
WO (1) WO1997046705A1 (en)

Families Citing this family (290)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998056952A1 (en) * 1997-06-09 1998-12-17 University Of Southern California A cancer diagnostic method based upon dna methylation differences
US6818404B2 (en) 1997-10-23 2004-11-16 Exact Sciences Corporation Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
DE19754482A1 (en) * 1997-11-27 1999-07-01 Epigenomics Gmbh Process for making complex DNA methylation fingerprints
AUPP312998A0 (en) * 1998-04-23 1998-05-14 Commonwealth Scientific And Industrial Research Organisation Diagnostic assay
US7700324B1 (en) * 1998-11-03 2010-04-20 The Johns Hopkins University School Of Medicine Methylated CpG island amplification (MCA)
US6994991B1 (en) 1998-11-18 2006-02-07 North Shore - Long Island Jewish Research Institute Identification of differentially methylated multiple drug resistance loci
DE19853398C1 (en) * 1998-11-19 2000-03-16 Epigenomics Gmbh Identification of 5-methylcytosine positions in genomic DNA by chemical modification, amplification and heteroduplex formation
DE19905082C1 (en) * 1999-01-29 2000-05-18 Epigenomics Gmbh Identification of methylation patterns of cytosine in genome DNA comprises chemical treatment to produce different base pairing behavior between cytosine and 5-methylcytosine
AUPP844899A0 (en) * 1999-02-01 1999-02-25 University Of Western Australia, The A method for detecting methylated nucleic acids
US7655443B1 (en) * 1999-05-07 2010-02-02 Siemens Healthcare Diagnostics, Inc. Nucleic acid sequencing with simultaneous quantitation
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
AU8021500A (en) * 1999-10-13 2001-04-23 Johns Hopkins University School Of Medicine, The Methods of diagnosing and treating hepatic cell proliferative disorders
US7332275B2 (en) * 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US20030207297A1 (en) * 1999-10-13 2003-11-06 Hubert Koster Methods for generating databases and databases for identifying polymorphic genetic markers
US6709818B1 (en) * 1999-10-13 2004-03-23 The Johns Hopkins University School Of Medicine Methods of diagnosing and treating hepatic cell proliferative disorders
JP2003517303A (en) * 1999-11-12 2003-05-27 エピゲノミクス アーゲー Controllable implementation of multiplex PCR amplification
DE19957827C2 (en) * 1999-11-25 2003-06-12 Epigenomics Ag Use of an oligomer array with PNA and / or DNA oligomers on a surface
US20030170649A1 (en) * 1999-12-03 2003-09-11 Haas Oskar A. Method for detecting and evaluating a potentially aberrantly methylated dna region on the x chromosome, or the clonality
DE19959691A1 (en) * 1999-12-06 2001-08-16 Epigenomics Ag Method for the parallel detection of the methylation state of genomic DNA
GB9929720D0 (en) * 1999-12-17 2000-02-09 Zeneca Ltd Diagnostic method
US8076063B2 (en) 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
DE10010282B4 (en) 2000-02-25 2006-11-16 Epigenomics Ag Method for the detection of cytosine methylation in DNA samples
DE10013847A1 (en) * 2000-03-15 2001-09-27 Epigenomics Ag Parallel detection of methylation in genomic DNA where DNA is chemically modified, fragmented, amplified and hybridized to probes, useful to investigate gene expression regulation
US20040067491A1 (en) * 2000-04-06 2004-04-08 Alexander Olek Diagnosis of diseases associated with metabolism
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
DE10029915B4 (en) * 2000-06-19 2005-06-16 Epigenomics Ag Method for the detection of cytosine methylations
WO2002002807A2 (en) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling
CA2312051A1 (en) 2000-07-13 2002-01-13 Quebepharma Inc. Methylated nucleotide regulation of gene expression
DE10038733A1 (en) * 2000-08-02 2002-02-21 Epigenomics Ag Procedure for determining the age of individuals
DE60136212D1 (en) * 2000-08-15 2008-11-27 Univ Johns Hopkins Med DIAGNOSIS AND TREATMENT OF TUMOR SUPPRESSOR ASSOCIATED DISEASES
CA2421102A1 (en) * 2000-08-25 2002-03-07 Lovelace Respiratory Research Institute Nested methylation-specific polymerase chain reaction cancer detection method
EP1320745A4 (en) * 2000-09-01 2008-10-01 Applera Corp System and method for temperature gradient capillary electrophoresis
CA2422890C (en) * 2000-09-29 2013-04-23 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
DE10050942B4 (en) * 2000-10-10 2005-11-17 Epigenomics Ag Method for the detection of cytosine methylations
AU2002214569A1 (en) * 2000-10-11 2002-04-22 Spectrumedix Corporation System and method for determining the presence of methylated cytosines in polynucleotides
GB0025913D0 (en) 2000-10-23 2000-12-06 Guldberg Per Materials and methods relating to nucleic acid amplification and profiling
AU1070002A (en) * 2000-10-23 2002-05-06 Cancer Res Ventures Ltd Materials and methods relating to nucleic acid amplification and profiling
CA2428245A1 (en) * 2000-11-08 2002-05-16 University Of Southern California A new assay for the detection and quantitation of hemimethylation
DE10056802B4 (en) * 2000-11-14 2005-06-16 Epigenomics Ag Method for the detection of methylation conditions for toxicological diagnostics
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US6893820B1 (en) * 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
JP2004536596A (en) * 2001-06-08 2004-12-09 ユー.エス. ジェノミクス, インコーポレイテッド Methods and products for analyzing nucleic acids based on methylation status
DE10128509A1 (en) * 2001-06-14 2003-01-02 Epigenomics Ag Methods and nucleic acids for the differentiation of prostate and kidney carcinomas
DE10128508A1 (en) * 2001-06-14 2003-02-06 Epigenomics Ag Methods and nucleic acids for the differentiation of prostate tumors
JP2005508885A (en) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン, アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Inhibitors of DNA methylation
DE10139283A1 (en) 2001-08-09 2003-03-13 Epigenomics Ag Methods and nucleic acids for the analysis of colon cancer
US6927028B2 (en) * 2001-08-31 2005-08-09 Chinese University Of Hong Kong Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA
DE10151055B4 (en) * 2001-10-05 2005-05-25 Epigenomics Ag Method for detecting cytosine methylation in CpG islands
WO2003031932A2 (en) * 2001-10-05 2003-04-17 Case Western Reserve University Methods and compositions for detecting colon cancers
WO2003033743A1 (en) * 2001-10-18 2003-04-24 Spectrumedix Corporation System and method for temperature gradient capillary electrophoresis
EP1442129B1 (en) * 2001-10-18 2008-09-10 Lovelace Respiratory Research Institute Cancer monitoring by aberrant promotor methylation of the transcription factor genes pax5 alpha pax5 beta, novel loop helix loop protein, novel gene 2, and beta3 genes
US20030099997A1 (en) * 2001-10-24 2003-05-29 Bestor Timothy H. Method for gene identification based on differential DNA methylation
DE10154317B4 (en) 2001-10-26 2005-06-09 Epigenomics Ag Method for the detection of cytosine methylations in immobilized DNA samples
EP1456413B1 (en) * 2001-11-16 2008-04-23 The Johns Hopkins University School Of Medicine Method of detection of prostate cancer
US20110151438A9 (en) 2001-11-19 2011-06-23 Affymetrix, Inc. Methods of Analysis of Methylation
EP1485399A4 (en) 2001-11-30 2008-01-02 Univ Johns Hopkins METHODS FOR ANALYZING METHYLATED CpG ISLANDS AND GC RICH REGIONS
DE10201138B4 (en) * 2002-01-08 2005-03-10 Epigenomics Ag Method for the detection of cytosine methylation patterns by exponential ligation of hybridized probe oligonucleotides (MLA)
WO2003064701A2 (en) * 2002-01-30 2003-08-07 Epigenomics Ag Method for the analysis of cytosine methylation patterns
US7776524B2 (en) * 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
KR100470221B1 (en) * 2002-02-20 2005-02-05 굿젠 주식회사 Minisequencing type oligonucleotide chip for detecting methylation of promoter CpG islands of multiple genes, method for preparing thereof and method for detecting cancer using the same
EP1340818A1 (en) * 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
DK1342794T3 (en) * 2002-03-05 2006-04-24 Epigenomics Ag Method and apparatus for determining tissue specificity of free-flowing DNA in body fluids
WO2003076666A1 (en) * 2002-03-08 2003-09-18 Naxcor Compositions and methods for detecting nucleic acid methylation
AU2003225983A1 (en) * 2002-03-25 2003-10-13 St. Jude Children's Research Hospital Cpg retrieval of dna from formalin-fixed pathology specimen for promoter methylation analysis
US6872530B2 (en) * 2002-04-24 2005-03-29 Spectrumedix, Llc Method for determining the presence of DNA variants using peptide nucleic acid probes
US7432342B2 (en) * 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
WO2003104427A2 (en) * 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
WO2004001307A1 (en) * 2002-06-21 2003-12-31 Hinode Co,. Ltd. Device for removing raindrops on umrella and system for promoting installation of the device
JP4384603B2 (en) * 2002-06-26 2009-12-16 コールド スプリング ハーバー ラボラトリー Methods and compositions for measuring methylation profiles
AU2003256579A1 (en) * 2002-07-16 2004-02-02 Spectrumedix Llc Method and system for comparative genomics for organisms using temperature gradient electrophoresis
ATE437962T1 (en) 2002-10-01 2009-08-15 Epigenomics Ag METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES OF BREAST CELLS
AU2003279101A1 (en) * 2002-10-02 2004-04-23 Northwestern University Methylation profile of cancer
US7238518B2 (en) 2002-10-04 2007-07-03 Nisshinbo Industries, Inc. Oligonucleotide-immobilized substrate for detecting methylation
WO2004050839A2 (en) 2002-11-27 2004-06-17 Sequenom, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
AU2003290223A1 (en) * 2002-12-02 2004-06-23 Solexa Limited Determination of methylation of nucleic acid sequences
US20040146868A1 (en) * 2003-01-24 2004-07-29 Epigenomics Ag Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the development of peripheral zone prostate cancer
AU2003900368A0 (en) * 2003-01-24 2003-02-13 Human Genetic Signatures Pty Ltd Assay for nucleic acid molecules
DE10304219B3 (en) * 2003-01-30 2004-08-19 Epigenomics Ag Method for the detection of cytosine methylation patterns with high sensitivity
US20070141570A1 (en) * 2003-03-07 2007-06-21 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
WO2004083399A2 (en) * 2003-03-17 2004-09-30 The Johns Hopkins University Aberrantly methylated genes in pancreatic cancer
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US20040203004A1 (en) * 2003-04-10 2004-10-14 Bernard Hans Ulrich Diagnostic apparatus and method
WO2004097369A2 (en) * 2003-04-25 2004-11-11 Sequenom, Inc. Fragmentation-based methods and systems for de novo sequencing
US7288373B2 (en) * 2003-05-02 2007-10-30 Human Genetic Signatures Pty Ltd. Treatment of methylated nucleic acid
US20050009059A1 (en) * 2003-05-07 2005-01-13 Affymetrix, Inc. Analysis of methylation status using oligonucleotide arrays
US8150626B2 (en) * 2003-05-15 2012-04-03 Illumina, Inc. Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns
US8150627B2 (en) 2003-05-15 2012-04-03 Illumina, Inc. Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns
WO2004110246A2 (en) * 2003-05-15 2004-12-23 Illumina, Inc. Methods and compositions for diagnosing conditions associated with specific dna methylation patterns
DE602004028478D1 (en) * 2003-06-17 2010-09-16 Human Genetic Signatures Pty PROCESS FOR GENOMA PLIFICATION
EP2354249A1 (en) 2003-06-23 2011-08-10 Epigenomics AG Methods and nucleic acids for analyses of colorectal cell proliferative disorders
WO2005001140A2 (en) 2003-06-23 2005-01-06 Epigenomics Ag Methods and nucleic acids for the analysis of colon cell proliferative disorders
EP2354248B1 (en) 2003-06-23 2018-01-03 Epigenomics AG Methods for analyses of colorectal cell proliferative disorders
US20040265833A1 (en) * 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
US20070117093A1 (en) * 2003-06-24 2007-05-24 Reimo Tetzner Heavymethyl assay for the methylation analysis of the gstpi gene
US7303879B2 (en) * 2003-07-31 2007-12-04 Applera Corporation Determination of SNP allelic frequencies using temperature gradient electrophoresis
EP1651778A1 (en) * 2003-08-01 2006-05-03 U.S. Genomics, Inc. Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions
US20060183128A1 (en) * 2003-08-12 2006-08-17 Epigenomics Ag Methods and compositions for differentiating tissues for cell types using epigenetic markers
US7485420B2 (en) * 2003-08-14 2009-02-03 Case Western Reserve University Methods and compositions for detecting colon cancers
US8415100B2 (en) 2003-08-14 2013-04-09 Case Western Reserve University Methods and compositions for detecting gastrointestinal and other cancers
DE10338308B4 (en) 2003-08-15 2006-10-19 Epigenomics Ag Method for the detection of cytosine methylations in DNA
US7198900B2 (en) 2003-08-29 2007-04-03 Applera Corporation Multiplex detection compositions, methods, and kits
JPWO2005021743A1 (en) * 2003-08-29 2007-11-01 松原 長秀 Nucleic acid amplification primer and colorectal cancer inspection method using the same
WO2005024053A1 (en) * 2003-09-04 2005-03-17 Human Genetic Signatures Pty Ltd Nucleic acid detection assay
WO2005024068A2 (en) * 2003-09-05 2005-03-17 Sequenom, Inc. Allele-specific sequence variation analysis
DE10348407A1 (en) * 2003-10-17 2005-05-19 Widschwendter, Martin, Prof. Prognostic and diagnostic markers for cell proliferative disorders of breast tissues
EP2339024B1 (en) 2003-10-21 2014-12-31 Orion Genomics, LLC Methods for quantitative determination of methylation density in a DNA locus
EP3269826B1 (en) 2003-12-01 2020-03-11 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
CA2487578A1 (en) 2003-12-11 2005-06-11 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
DE102004002257B4 (en) * 2004-01-09 2006-11-09 Epigenomics Ag Method for studying cytosine methylations in DNA using DNA repair enzymes
AU2005213318B2 (en) * 2004-02-10 2010-06-10 Cornell Research Foundation, Inc. Method for detection of promoter methylation status
WO2005085477A1 (en) * 2004-03-02 2005-09-15 Orion Genomics Llc Differential enzymatic fragmentation by whole genome amplification
US7608394B2 (en) 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
CA2561381C (en) * 2004-03-26 2015-05-12 Sequenom, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
WO2005118872A2 (en) * 2004-06-01 2005-12-15 The Regents Of The University Of Michigan Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US7943308B2 (en) 2004-06-23 2011-05-17 Epigenomics Ag Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
EP1961827A3 (en) 2004-07-18 2008-09-17 Epigenomics AG Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
US7981607B2 (en) * 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
AU2005284980A1 (en) * 2004-09-10 2006-03-23 Sequenom, Inc. Methods for long-range sequence analysis of nucleic acids
ATE476439T1 (en) * 2004-09-10 2010-08-15 Human Genetic Signatures Pty AMPLIFICATION BLOCKERS COMPRISING INTERCALATING NUCLEIC ACIDS (INA) CONTAINING INTERCALATING PSEUDONUCLEOTIDES (IPN)
KR100617649B1 (en) 2004-09-24 2006-09-04 (주)지노믹트리 Composition For Cancer diagnosis Containing Methylated Promoters of Colon Cancer Specific Expression-decreased Genes and Use Thereof
EP1812589A2 (en) * 2004-09-30 2007-08-01 Epigenomics AG Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
EP1830845A2 (en) * 2004-11-09 2007-09-12 Shering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
US20060122162A1 (en) * 2004-12-02 2006-06-08 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
EP1831399B1 (en) * 2004-12-02 2009-08-05 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
DK1828411T3 (en) * 2004-12-03 2013-02-18 Human Genetic Signatures Pty Process for simplifying microbial nucleic acids by chemically modifying cytosines
CA2592993C (en) 2004-12-13 2013-06-18 National University Corporation Okayama University Method for detecting methylation in genes and method for examining neoplasm through detecting methylation in genes
US20060134650A1 (en) * 2004-12-21 2006-06-22 Illumina, Inc. Methylation-sensitive restriction enzyme endonuclease method of whole genome methylation analysis
US20090029346A1 (en) * 2004-12-23 2009-01-29 Human Genetic Signatures Pty., Ltd. Detection of human papilloma virus
EP1869212A4 (en) 2005-02-01 2009-09-23 Wayne John Cancer Inst Use of id4 for diagnosis and treatment of cancer
EP1853727A4 (en) 2005-02-14 2010-01-06 Univ Johns Hopkins Neoplasia screening compositions and methods of use
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
KR100735045B1 (en) 2005-04-07 2007-07-03 (주) 차바이오텍 1 A method for measuring DNA methylation using by mouse B1 element and the efficiency of anti-cancer agent thereby
JP5341506B2 (en) 2005-04-15 2013-11-13 エピゲノミクス アーゲー Methods and nucleic acids for cell proliferative disease analysis
WO2007044071A2 (en) * 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
EP2345743A1 (en) 2005-05-02 2011-07-20 University of Southern California DNA methylation markers associated with the CpG island methylator phenotyp (CIMP) in human colorectal cancer
US8431347B2 (en) * 2005-05-26 2013-04-30 Human Genetic Signatures Pty Ltd Isothermal strand displacement amplification using primers containing a non-regular base
US7439024B2 (en) * 2005-06-01 2008-10-21 The United States Of America As Represented By The Department Of Veterans Affairs Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US20070037184A1 (en) * 2005-06-16 2007-02-15 Applera Corporation Methods and kits for evaluating dna methylation
US20060286577A1 (en) * 2005-06-17 2006-12-21 Xiyu Jia Methods for detection of methylated DNA
US20070087360A1 (en) * 2005-06-20 2007-04-19 Boyd Victoria L Methods and compositions for detecting nucleotides
US20060292585A1 (en) * 2005-06-24 2006-12-28 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
EP1907855A4 (en) * 2005-07-12 2009-11-11 Univ Temple Genetic and epigenetic alterations in the diagnosis and treatment of cancer
EP1904649A2 (en) * 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
AU2006292033B2 (en) * 2005-09-14 2010-08-12 Human Genetic Signatures Pty Ltd Assay for a health state
US20070059753A1 (en) * 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
WO2007039128A1 (en) * 2005-09-21 2007-04-12 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20090191548A1 (en) 2005-09-29 2009-07-30 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with tissue classification
WO2007039290A2 (en) * 2005-10-03 2007-04-12 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
US20090042195A1 (en) * 2005-10-07 2009-02-12 Bradford Coffee Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies
US7770717B2 (en) * 2005-10-12 2010-08-10 Scanvaegt International A/S Device for transfer of items
US20070087358A1 (en) * 2005-10-19 2007-04-19 Melanie Ehrlich Methods for diagnosing cancer based on DNA methylation status in NBL2
WO2007102891A2 (en) * 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
EP3095878A1 (en) * 2005-11-17 2016-11-23 Epigenomics AG Method for the determination of the dna methylation level of a cpg position in identical cells within a tissue sample
EA201200560A1 (en) 2006-01-18 2012-09-28 Мерк Патент Гмбх SPECIFIC THERAPY USING INTEGRINE LIGANDS FOR CANCER TREATMENT
US7820385B2 (en) * 2006-03-22 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention Method for retaining methylation pattern in globally amplified DNA
EP2004860A4 (en) * 2006-03-29 2009-12-30 Wayne John Cancer Inst Methylation of estrogen receptor alpha and uses thereof
EP1840224A1 (en) 2006-03-29 2007-10-03 Pangaea Biotech, S.A. Method of predicting survival of a non-small-cell lung cancer patient to a chemotherapeutic treatment
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
WO2007118704A2 (en) 2006-04-17 2007-10-25 Epigenomics Ag Methods and nucleic acids for the detection of colorectal cell proliferative disorders
US20090317810A1 (en) * 2006-04-17 2009-12-24 Epigenomics Ag Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2007133496A2 (en) * 2006-05-09 2007-11-22 Schering Corporation Development of a novel assay for mgmt (methyl guanine transferase)
US20080003609A1 (en) * 2006-05-10 2008-01-03 The Cleveland Clinic Foundation Method of detecting bladder urothelial carcinoma
US20080081333A1 (en) * 2006-05-26 2008-04-03 University Of Maryland, Baltimore Methylated promoters as biomarkers of colon cancer
KR100761031B1 (en) 2006-05-27 2007-10-04 김연수 Cancer Detection Kit Using the DNA Methylation
US20080050738A1 (en) * 2006-05-31 2008-02-28 Human Genetic Signatures Pty Ltd. Detection of target nucleic acid
WO2008010975A2 (en) * 2006-07-14 2008-01-24 The Johns Hopkins University Early detection and prognosis of colon cancers
ES2546182T3 (en) * 2006-07-21 2015-09-21 Epigenomics Ag Methods and kits for methylation analysis in colorectal cell proliferative disorders
EP2102361B1 (en) 2006-11-20 2015-07-08 The Johns Hopkins University Dna methylation markers and methods of use
EP2099938B1 (en) 2006-11-24 2016-11-16 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
CA2675895C (en) 2007-01-19 2016-03-22 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
US20090203011A1 (en) * 2007-01-19 2009-08-13 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
WO2008096146A1 (en) * 2007-02-07 2008-08-14 Solexa Limited Preparation of templates for methylation analysis
CN101680033A (en) * 2007-03-16 2010-03-24 人类遗传标记控股有限公司 The measuring method of genetic expression
US9290803B2 (en) 2007-04-12 2016-03-22 University Of Southern California DNA methylation analysis by digital bisulfite genomic sequencing and digital methylight
EP2339022A3 (en) * 2007-04-25 2011-10-26 John Wayne Cancer Institute Use of methylated or unmethylated line-1 DNA as a cancer marker
AU2008251921A1 (en) 2007-05-08 2008-11-20 Merck Sharp & Dohme Corp. Methods of treatment using intravenous formulations comprising temozolomide
US9271455B2 (en) * 2007-05-31 2016-03-01 Monsanto Technology Llc Soybean polymorphisms and methods of genotyping
CA2687171A1 (en) * 2007-06-08 2008-12-11 Bio-Dixam, Llc Amplification method of methylated or unmethylated nucleic acid
JP5512521B2 (en) * 2007-09-17 2014-06-04 コーニンクレッカ フィリップス エヌ ヴェ Analysis method of ovarian cancer disease
PL2198042T3 (en) 2007-09-17 2017-05-31 Mdxhealth Sa Novel markers for bladder cancer detection
EP2193209B1 (en) * 2007-09-17 2014-11-12 Koninklijke Philips N.V. Method for the analysis of breast cancer disorders
EP2215250B1 (en) * 2007-11-27 2013-02-27 Human Genetic Signatures Pty Ltd Enzymes for amplification and copying bisulphite modified nucleic acids
JP5694776B2 (en) 2007-12-11 2015-04-01 エピゲノミクス アーゲー Methods and nucleic acids for analysis of cell proliferative disorders
JP2011505845A (en) * 2007-12-20 2011-03-03 ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド Eliminate contaminants associated with nucleic acid amplification
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2009105549A2 (en) 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20110189653A1 (en) 2008-03-21 2011-08-04 Wim Van Criekinge Detection and prognosis of cervical cancer
EP2290064A4 (en) * 2008-04-14 2011-10-12 Univ Nihon Proliferative disease detection method
BRPI0913578A2 (en) 2008-05-14 2017-06-06 Dermtech Int diagnosis of melanoma and solar lentigo by nucleic acid analysis
EP2304057B1 (en) 2008-06-17 2014-09-17 Signature Diagnostics AG Method for the detection of ovarian cancer
US8541207B2 (en) 2008-10-22 2013-09-24 Illumina, Inc. Preservation of information related to genomic DNA methylation
WO2010070572A1 (en) 2008-12-18 2010-06-24 Koninklijke Philips Electronics N. V. Method for the detection of dna methylation patterns
DK2210954T3 (en) 2009-01-22 2011-10-10 Univ Duesseldorf H Heine Determination of DNA methylation level
DK2394170T3 (en) 2009-02-03 2015-07-13 Mdxhealth Sa Methods for detecting colorectal cancer
EP2406393B1 (en) 2009-03-13 2016-05-04 MDxHealth SA Novel markers for bladder cancer detection
WO2010105815A2 (en) 2009-03-17 2010-09-23 Oncomethylome Sciences S.A. Improved detection of gene expression
EP3048176B1 (en) 2009-04-20 2019-03-06 Erasmus University Medical Center Rotterdam Method of diagnosing bladder cancer
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
ES2669439T3 (en) 2009-06-26 2018-05-25 Epigenomics Ag Methods and nucleic acids for bladder carcinoma analysis
ES2534200T3 (en) * 2009-08-03 2015-04-20 Epigenomics Ag Methods for preserving the complexity of the genomic DNA sequence
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
WO2011036173A1 (en) 2009-09-24 2011-03-31 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
US8399138B2 (en) * 2009-10-14 2013-03-19 GM Global Technology Operations LLC Liquid rechargeable lithium ion battery
WO2011051414A1 (en) 2009-10-28 2011-05-05 Signature Diagnostics Ag Method for the prognosis of ovarian carcinoma
US20110104695A1 (en) 2009-11-05 2011-05-05 Epigenomics Ag Methods of predicting therapeutic efficacy of cancer therapy
JP2013511991A (en) * 2009-11-25 2013-04-11 クアンタライフ, インコーポレイテッド Methods and compositions for detecting genetic material
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
MA34263B1 (en) 2010-04-30 2013-05-02 Novartis Ag PREDICTION MARKERS USEFUL IN TREATING FRAGILE X (FXS) SYNDROME
WO2011135058A2 (en) 2010-04-30 2011-11-03 Mdxhealth Sa Methods for detecting epigenetic modifications
EP2576832B1 (en) 2010-05-25 2016-05-04 The Johns Hopkins University Compositions and methods for detecting a neoplasia
US9220771B2 (en) 2010-07-16 2015-12-29 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
US9637792B2 (en) 2011-02-02 2017-05-02 Mayo Foundation For Medical Education And Research Digital sequence analysis of DNA methylation
JP2014506465A (en) 2011-02-09 2014-03-17 バイオ−ラド ラボラトリーズ,インコーポレイティド Nucleic acid analysis
WO2012162139A1 (en) 2011-05-20 2012-11-29 The Regents Of The University Of California Method to estimate age of individual based on epigenetic markers in biological sample
JP6397762B2 (en) 2011-07-08 2018-09-26 エピゲノミクス アーゲー Method for determining prognosis of cancer subject and nucleic acid
KR101912488B1 (en) 2011-09-07 2018-10-26 휴먼 제네틱 시그너처스 피티와이 엘티디 Molecular detection assay
WO2013084075A2 (en) 2011-12-06 2013-06-13 Mdxhealth Sa Methods of detecting mutations and epigenetic changes
WO2013096661A1 (en) 2011-12-22 2013-06-27 Illumina, Inc. Methylation biomarkers for ovarian cancer
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
EP2644705A1 (en) 2012-03-30 2013-10-02 RWTH Aachen Biomarker for bladder cancer
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
MX2014014356A (en) 2012-05-24 2015-07-06 Fundació Inst D Investigació Biomédica De Bellvitge Idibell Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis.
EP2859353B1 (en) 2012-06-11 2018-09-12 Medizinische Hochschule Hannover Susceptibility to and stratification for monoaminergic antidepressants
US20140272967A1 (en) 2013-03-13 2014-09-18 Abbott Molecular Inc. Systems and methods for isolating nucleic acids
US9701999B2 (en) 2013-03-14 2017-07-11 Abbott Molecular, Inc. Multiplex methylation-specific amplification systems and methods
EP3543360B1 (en) 2013-03-14 2021-02-17 Mayo Foundation for Medical Education and Research Detecting neoplasm
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
CN104250663B (en) * 2013-06-27 2017-09-15 北京大学 The high-flux sequence detection method on methylated CpG island
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2015124921A1 (en) 2014-02-19 2015-08-27 The University Court Of The University Of Edinburgh Methods and uses for determining the presence of inflammatory bowel disease
CN106460046A (en) 2014-03-31 2017-02-22 梅奥医学教育和研究基金会 Detecting colorectal neoplasm
EP3140420B1 (en) 2014-05-07 2019-09-11 Universite Libre De Bruxelles Breast cancer epigenetic markers useful in anthracycline treatment prognosis
EP2942401A1 (en) 2014-05-09 2015-11-11 Lifecodexx AG Detection of DNA that originates from a specific cell-type
EP2942400A1 (en) 2014-05-09 2015-11-11 Lifecodexx AG Multiplex detection of DNA that originates from a specific cell-type
CA2985134A1 (en) 2014-05-09 2015-11-12 Sebastian Gromminger Detection of dna that originates from a specific cell-type and related methods
US10465249B2 (en) 2014-12-12 2019-11-05 Exact Sciences Development Company, Llc Method of characterizing ZDHHC1 DNA
US9984201B2 (en) 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation Detecting esophageal disorders
US10683547B2 (en) 2015-05-29 2020-06-16 Vito Nv Epigenetic markers for respiratory allergy
GB201510684D0 (en) 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
EP3162899A1 (en) 2015-10-29 2017-05-03 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Biomarker for breast cancer
EP3998353A1 (en) 2015-10-30 2022-05-18 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of dna from plasma
HUE050491T2 (en) 2015-11-10 2020-12-28 Eurofins Lifecodexx Gmbh Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female
CN115881230A (en) 2015-12-17 2023-03-31 伊路敏纳公司 Differentiating methylation levels in complex biological samples
WO2017136482A1 (en) 2016-02-01 2017-08-10 The Board Of Regents Of The University Of Nebraska Method of identifying important methylome features and use thereof
CN109563546B (en) 2016-05-05 2022-09-09 精密科学发展有限责任公司 Detection of lung tumors by analysis of methylated DNA
DE102016005947B3 (en) 2016-05-16 2017-06-08 Dimo Dietrich A method for estimating the prognosis and predicting the response to immunotherapy of patients with malignant diseases
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
WO2017210341A1 (en) 2016-05-31 2017-12-07 The Regents Of The University Of California Methods for evaluating, monitoring, and modulating aging process
US10093986B2 (en) 2016-07-06 2018-10-09 Youhealth Biotech, Limited Leukemia methylation markers and uses thereof
EP3481403B1 (en) 2016-07-06 2022-02-09 Youhealth Biotech, Limited Solid tumor methylation markers and uses thereof
WO2018009703A1 (en) 2016-07-06 2018-01-11 Youhealth Biotech, Limited Breast and ovarian cancer methylation markers and uses thereof
CN106011278B (en) * 2016-07-18 2020-01-21 宁波大学医学院附属医院 Detection reagent for PIEZO2 gene in human gastrointestinal tumor
US11345949B2 (en) 2016-07-19 2022-05-31 Exact Sciences Corporation Methylated control DNA
CA3034903A1 (en) 2016-09-02 2018-03-08 Mayo Foundation For Medical Education And Research Detecting hepatocellular carcinoma
DK3336197T3 (en) 2016-12-16 2022-07-11 Eurofins Genomics Europe Sequencing GmbH EPIGENETIC MARKERS AND RELATED METHODS AND AGENTS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER
JP7289264B2 (en) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション Detection of Colon Tumors by Analysis of Methylated DNA
CN110603329B (en) 2017-03-02 2023-12-05 优美佳肿瘤技术有限公司 Methylation markers for diagnosing hepatocellular carcinoma and lung cancer
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3652338A1 (en) 2017-07-14 2020-05-20 Universite Libre De Bruxelles Method for predicting responsiveness to immunotherapy
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
DE102017125780B3 (en) 2017-11-05 2018-12-13 Dimo Dietrich Method for determining the response of a malignant disease to immunotherapy
US11648551B2 (en) 2017-12-12 2023-05-16 Essenlix Corporation Sample manipulation and assay with rapid temperature change
WO2020099938A2 (en) 2018-11-16 2020-05-22 Oslo Universitetssykehus Hf Methods and compositions for characterizing bladder cancer
JP7320067B2 (en) 2019-01-18 2023-08-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア DNA methylation measurements for mammals based on conserved loci
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
US11396679B2 (en) 2019-05-31 2022-07-26 Universal Diagnostics, S.L. Detection of colorectal cancer
US11001898B2 (en) 2019-05-31 2021-05-11 Universal Diagnostics, S.L. Detection of colorectal cancer
US20220290245A1 (en) 2019-09-11 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Cancer detection and classification
CN114729399A (en) 2019-10-31 2022-07-08 梅约医学教育与研究基金会 Detection of ovarian cancer
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
CA3173044A1 (en) 2020-03-20 2021-09-23 Singlera Health Technologies (Shanghai) Ltd. Methods and kits for screening colorectal neoplasm
US11530453B2 (en) 2020-06-30 2022-12-20 Universal Diagnostics, S.L. Systems and methods for detection of multiple cancer types
CN116670299A (en) 2020-08-19 2023-08-29 梅约医学教育与研究基金会 Detection of non-hodgkin lymphomas
EP4284951A1 (en) 2021-01-29 2023-12-06 Mayo Foundation for Medical Education and Research Detecting the presence or absence of multiple types of cancer
WO2023052640A1 (en) 2021-09-30 2023-04-06 Tivenix Sa A method for diagnosing and predicting progression of neurodegenerative diseases or disorders
WO2023066972A1 (en) 2021-10-19 2023-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Dna methylation signature for diagnosing hepatocellular carcinoma
EP4170661A1 (en) 2021-10-19 2023-04-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Methylation profile analysis using smoothing method
WO2023175019A1 (en) 2022-03-15 2023-09-21 Genknowme S.A. Method determining the difference between the biological age and the chronological age of a subject
EP4299764A1 (en) 2022-06-28 2024-01-03 Universal Diagnostics, S.A. Methods for detecting pancreatic cancer using dna methylation markers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JP3156082B2 (en) * 1989-03-21 2001-04-16 アメリカ合衆国 Matrix metalloproteinase inhibitor peptide
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
IL108978A (en) * 1994-03-15 1998-02-22 Yissum Res Dev Co Assay for monitoring the progress of cml
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5871917A (en) * 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids

Also Published As

Publication number Publication date
EP0954608B1 (en) 2006-05-17
JP3725535B2 (en) 2005-12-14
PT954608E (en) 2006-08-31
JP3612080B2 (en) 2005-01-19
EP0954608A1 (en) 1999-11-10
US6265171B1 (en) 2001-07-24
US6017704A (en) 2000-01-25
EP0954608A4 (en) 2003-09-10
ES2264165T3 (en) 2006-12-16
JP2000511776A (en) 2000-09-12
DE69735894D1 (en) 2006-06-22
EP1690948A3 (en) 2006-11-22
DE69735894T2 (en) 2007-04-19
IL127342A0 (en) 1999-10-28
DK0954608T3 (en) 2006-08-21
CA2257104A1 (en) 1997-12-11
ATE326549T1 (en) 2006-06-15
JP2004290200A (en) 2004-10-21
WO1997046705A1 (en) 1997-12-11
EP1690948A2 (en) 2006-08-16
IL127342A (en) 2002-07-25

Similar Documents

Publication Publication Date Title
CA2257104C (en) Methylation specific detection
EP0672181B1 (en) Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
US5786146A (en) Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US7601521B2 (en) Detection of nucleic acid mutation associated with cancer by analysis of saliva
US8785614B2 (en) Aberrantly methylated genes in pancreatic cancer
JP3522690B2 (en) GST-Pi gene methylation assay
US20060194250A1 (en) Cancer diagnostic method based upon DNA methylation differences
JPH10506527A (en) Detection of highly mutable nucleic acid sequences in tissues
JP2005204652A (en) Assay for detecting methylation status by methylation specific primer extension (mspe)
US6180344B1 (en) 5′ Upstream region sequences of the MyoD1 gene and uses thereof
CA2612690C (en) Methylation specific detection
US7611841B2 (en) Method for detecting methylation of promoter using restriction enzyme and DNA chip
AU774182B2 (en) Automatable rapid test for detecting cancers, on the basis of telomerase(hTC) mRNA and specific primers and probes
US6207376B1 (en) Method of detection of polymorphism and loss of heterozygosity in a lung tumor suppressor gene
Dong Molecular genetic studies of oligodendroglial tumors

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170605